The role of PATZ1 transcription factor in the DNA damage response by Deniz, Emre
  
 
THE ROLE OF PATZ1 TRANSCRIPTION FACTOR  
IN THE DNA DAMAGE RESPONSE 
 
 
 
 
 
by 
EMRE DENİZ 
 
 
 
Submitted to the  
Graduate School of Engineering and Natural Sciences  
in partial fulfillment of  
the requirements for the degree of  
Doctor of Philosophy 
 
Sabanci University 
July 2014 
  
ii 
 
THE ROLE OF PATZ1 TRANSCRIPTION FACTOR  
IN THE DNA DAMAGE RESPONSE  
 
 
 
APPROVED BY: 
 
Assoc. Prof. Dr. Batu Erman  ............................................................... 
          (Thesis Supervisor) 
 
 
Asst. Prof. Dr. Alpay Taralp  ................................................................ 
 
 
 
Assoc. Prof. Dr. Murat Çokol  ................................................................ 
 
 
Prof. Dr. Selim Çetiner   ................................................................ 
 
 
Asst. Prof. Dr. Stefan H. Fuss  ................................................................ 
 
 
 
 
DATE OF APPROVAL: 22.07.2014 
 
 
iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Emre Deniz 2014 
All Rights Reserved  
iv 
 
ABSTRACT 
 
 
 
THE ROLE OF PATZ1 TRANSCRIPTION FACTOR 
IN THE DNA DAMAGE RESPONSE 
 
 
Emre Deniz 
Biological Sciences and Bioengineering, PhD Thesis, 2014  
Thesis supervisor: Batu Erman 
Keywords: PATZ1, p53, DNA Damage, Tumorigenesis, RNA-Seq 
 
 
 PATZ1 (MAZR) is a transcription factor composed of an N-terminal BTB 
protein-protein interaction domain and a C-terminal zinc finger and AT-hook DNA 
binding domain. Recent findings indicate that PATZ1 has a crucial role in the p53 
pathway and during tumorigenesis. PATZ1 interacts with p53, is upregulated in various 
cancers and its absence favors lymphomagenesis. We identified a role for PATZ1 as a 
regulator of the p53 tumor suppressor protein. We found that upon doxorubicin induced 
DNA damage, the protein level of PATZ1 decreases, as the p53 protein accumulates. 
This inverse correlation between PATZ1 and p53 protein levels led us to investigate the 
biological relevance of these two proteins. We found that PATZ1 loss resulted in 
decreased proliferation rates in various cell types; while its overexpression accelerated 
proliferation. We demonstrate that PATZ1 inhibits the transcription activation function 
of p53 by luciferase reporter assays. While p53 is responsible for inducing the 
expression of the target genes p21 and Puma, we show that PATZ1 overexpressing cells 
cannot induce the expression of these genes as effectively as wild type cells. Finally, we 
performed genome scale RNA-Seq and microarray analysis on doxorubicin treated 
mouse embryo fibroblasts sufficient or deficient for PATZ1 and found that the absence 
of PATZ1 results in an alteration of the expression of p53 target genes. These results 
demonstrate that PATZ1 modulates p53-dependent cellular stress and DNA damage 
pathways. 
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ÖZET 
 
 
 
PATZ1 TRANSKRİPSİYON FAKTÖRÜNÜN  
DNA HASAR YANITLARINDAKİ ROLÜ 
 
 
Emre Deniz 
Biyoloji Bilimleri ve Biyomühendislik, Doktora Tezi, 2014  
Tez Danışmanı: Batu Erman 
Anahtar Kelimeler: PATZ1, p53, DNA Hasarı, Tümör Gelişimi, RNA-Sek 
 
 
 PATZ1 (MAZR), N ucunda protein-protein etkileşimlerinde görevli BTB 
bölgesi, C ucunda ise çinko parmak ve AT-hook motifleri olan bir transkripsiyon 
faktörüdür. Son zamanlarda bulunan bilgilere göre, PATZ1, p53 yolağında ve tümör 
gelişimi sırasında kritik rollere sahiptir. PATZ1 proteini p53 proteinine bağlanır, çeşitli 
kanser tiplerinde yüksek miktarda ifade edilir ve PATZ1’in yokluğunda lenfoma 
gelişimi kolaylaşır. Biz, PATZ1’i tümör baskılayıcı p53 proteininin düzenleyicisi olarak 
belirledik. Doksorubisin ilacı ile indüklediğimiz DNA hasarı sonucunda, hücre 
içerisinde p53 proteini birikirken, PATZ1 proteininin azaldığını bulduk. PATZ1 ve p53 
miktarlarının değişimindeki ters ilişki bizi bu iki proteinin biyolojik etkileşimlerini 
araştırmaya teşvik etti. PATZ1’in aşırı miktarda ifadesinin çeşitli hücre tiplerinde 
bölünmeyi hızlandırdığını, ifadesinin düşük olmasının ise hücre bölünmesini 
yavaşlattığını bulduk. Yaptığımız lusiferaz aktivitesi deneyleri sonucunda, PATZ1’in 
p53’ün transkripsiyon etkinleştirici fonksiyonunu engellediğini kanıtladık. Normalde, 
p53, p21 ve Puma genlerinin ifadelerini arttırmasına rağmen, PATZ1’i aşırı miktarda 
ifade eden hücrelerin bu genleri normal durumdaki kadar arttıramadığını gösterdik. Son 
olarak, PATZ1’in yeterli veya yetersiz ifade ediliği fare embriyo fibroblastlarını 
doksorubisin ile muamele ederek genom çapında RNA-Seq ve mikroarray analizleri 
gerçekleştirdik ve PATZ1’in yetersiz olduğu durumdalarda p53 hedeflerinin 
ifadelerinde farklılaşmalar olduğunu bulduk. Bu sonuçlar ile PATZ1’in p53 temelli 
hücre stresi ve DNA hasar yolaklarını düzenlediğini kanıtladık.  
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1. INTRODUCTION 
 
 
 
 
1.1. Tumor Suppressor Protein p53 
 
 
 
Since the discovery of p53 35 years ago, there have been a substantial number of 
studies on this tumor suppressor protein. Pubmed alone lists over 72000 scientific 
publications and this archive is ever-growing. This immense amount of work on a single 
protein points to the importance of p53 in maintaining a wide variety of processes 
within eukaryotic cells. p53 is a sequence specific, cellular stress responsive 
transcription factor that plays key roles in many important cellular responses. Among 
these responses are cell cycle arrest, senescence, DNA repair and recombination, 
autophagy, and apoptosis. 
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1.1.1. Paradigm Shift: from an Oncogene to a Tumor Suppressor 
 
 
In 1979, several different laboratories independently identified a 53-54 kDa 
protein as an interaction partner of the oncogenic large T antigen protein of the SV40 
virus 1–5. Following this work, other groups found that p53 cooperated with different 
oncogenic proteins, such as the adenovirus E1b-57K protein, activated Ha-Ras, and the 
v-myc protein of the myelocytomatosis virus 6–8. In addition to these, p53 was found to 
be overexpressed in different human cancer cell lines 9. All these observations 
suggested that p53 itself was indeed an oncogene. However, later on, frequent genetic 
alterations and loss-of-heterozygosity of the p53 gene locus (TP53) were found in many 
human colorectal cancers 10. Along with this finding, various groups observed that cells 
transfected with wild type p53 rarely were transformed and the few transformed clones 
expressed mutant p53 instead of WT protein 11,12. These findings identified p53 as a 
tumor suppressor protein rather than an oncogene. 
 
After this paradigm shift, a large amount of work corroborated the latter 
findings, showing that in various systems, p53 was indeed a tumor suppressor protein 13. 
It is widely quoted that TP53 is mutated in almost 50% of human tumors and that 
patients with mutant p53 tumors respond poorly to therapy 14,15. While this number is 
impressive, it is likely an underestimation of the impact of p53 protein on tumors, 
because those tumors which have WT p53 often activate p53 suppressor mechanisms 16. 
Germline mutations in the TP53 gene in humans cause Li-Fraumeni syndrome, which is 
an inherited disease characterized by a high rate of malignant tumors of different tissues 
17. Mouse models of knock-out Trp53 are highly prone to spontaneous tumor 
development 18,19. These mice often develop lymphomas but the types of the tumors 
observed are widely variable 19. Acquiring a mutant p53 allele, either through inheriting 
or from a spontaneous mutation, usually leads to the loss of the remaining WT allele, 
which is called loss of heterozygosity (LOH) 20. Most of the p53 mutations that result in 
tumor development are missense mutations, a single nucleotide change in the protein 
coding sequence causing a single amino acid change in the protein 21. Many mutant p53 
proteins function as dominant-negative on WT p53, thereby inhibiting the tumor 
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suppressor activity of WT p53, and/or acquire gain-of-functions (GOF), which retain 
only a part of the WT p53 activity that may be beneficial for tumor progression, or 
provoke activation of a new set of target genes 22. All these accumulated data over 3 
decades secured the critical place of p53 in tumorigenesis and firmly implied that p53 is 
a tumor suppressor protein. 
 
 
 
1.1.2. Structure of p53 
 
 
The human TP53 gene is located on the short arm (p13.1) of chromosome 17. 
The gene spans 19200bps and consists of 11 exons (Ensembl accession number 
ENSG00000141510). It is predicted that from this gene 17 mRNAs are transcribed 
while only 12 of these encode proteins. The most abundant isoform of p53 is the 
canonical p53 protein, which is formally named TAp53α (this isoform will be referred 
to as p53 throughout this thesis, for the sake of simplicity). p53 encodes a 393 amino 
acid long 53 kDa protein. p53 consists of several conserved and functionally relevant 
domains 23 (Figure 1.1). Starting from the very first N-terminal amino acid, there are 
two transactivation domains (TAD1 and TAD2). TAD1 spans residues 1-42, and TAD2 
spans residues 43-62. Following the TADs, there is a proline rich domain (PRD) 
spanning residues 63-97. After the N-terminal part of the protein, a central core part is 
located from residue 98 to 292, which encodes a DNA binding domain (DBD). The C-
terminal part of the protein has a nuclear localization signal (NLS) spanning residues 
300-323, a tetramerization domain (TD) spanning residues 324-355, a nuclear export 
signal (NES) spanning residues 356-362, followed by an unstructured regulatory 
domain in the very C-terminus of the protein. 
 
The TAD1 has sites for recruiting coactivators needed for transcriptional 
activation and it also binds to MDM2, which is the most critical E3 ligase for p53 that 
governs the levels of cellular p53 protein 24. The TAD2, on the other hand, is not as 
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important as TAD1, but it also interacts with coactivators and dictates p53 to induce 
specific target genes 25. The PRD interacts with SH3-domain proteins. MDM2 and p300 
also bind to this region and this interaction functions to fine-tune p53 stabilization and 
transactivation 26,27. 
 
 
Figure 1.1: The protein structure of the canonical p53 isoform. The full length protein 
consists of 393 amino acids and has an estimated size of 53 kDa. The conserved and 
functional domains from the N-terminus of the protein to the C-terminus are the 
following; two transactivation domains (TAD1 and TAD2), a proline rich domain 
(PRD), a DNA binding domain (DBD), a nuclear localization signal (NLS), a 
tetramerization domain (TD), a nuclear export signal (NES), and an unstructured C-
terminal regulatory domain. 
 
The DBD has a high affinity to various p53 response elements (RE) in the 
genome. The REs are composed of two half-sites, each with a consensus of 5'-
PuPuPuC(A/T)(T/A)GPyPyPy-3', separated by 0-13 bases (where Pu is a purine, Py is a 
pyrimidine) 28. Most of the mutations in human tumors that alter the function of p53 are 
located within this DBD, causing mis-targeting of p53 to a new set of target genes or 
impairing DNA binding of p53 completely 29.  
 
The TD is necessary to form tetramers of the p53 protein. While p53 can bind to 
DNA as dimers or tetramers, it is transcriptionally active only when it oligomerizes into 
tetramers 30. Tetramerization is also important in masking the nuclear export signal, 
thereby ensuring nuclear retention of the transcriptionally active form of p53 31. The C-
terminal regulatory domain of p53 is extensively and specifically post-translationally 
modified in response to cellular stress. The different modifications of this domain 
determine the interaction partners of the p53 protein, akin to the histone code 32. The 
regulatory domain was shown to have two functions. First, it modulates overall p53 
protein stability by post-translational modifications of the lysine residues within this 
domain 33. Secondly, this domain nonspecifically interacts with DNA and promotes the 
sequence specificity of the DNA binding domain 34.  
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1.1.3. Regulation of p53 Stabilization 
 
 
The mRNA levels of p53 do not change upon stress. Rather, the stabilization or 
degradation of the protein is what determines the levels of the cellular p53. Under 
normal conditions, without any cellular stress, the level of p53 protein is low in cells 
due to degradation. Upon a variety of stresses, p53 protein is rapidly stabilized and 
activated. There are a number of factors that control the stability and activity of p53 in 
normal and stressed cells. Ubiquitination of p53 has a marked impact on the stability 
and localization of this protein. While mono-ubiquitination targets p53 out of the 
nucleus to the cytoplasm, poly-ubiquitination serves as a signal for degradation by the 
26S proteosome 35. The major mechanism for controlling p53 stability is its interaction 
with MDM2 36,37. MDM2 is a RING finger E3 ubiquitin-protein ligase. In the nucleus, it 
mono-ubiquitinates p53 at the C-terminal K370, K372, K373, K381, K382, and K386 
residues, unmasking the NES of p53 within the C-terminus and driving the protein out 
of the nucleus 38. While nuclear MDM2 does not travel to the cytoplasm along with the 
mono-ubiquitinated p53, cytoplasmic MDM2 continues to poly-ubiquitinate 
cytoplasmic p53 (Figure 1.2). The targeted inactivation (knock out) of the MDM2 
protein in mice causes embryonic lethality; however, this phenotype is rescued when 
MDM2-/- mice are bred with p53-/- mice 36,37. These findings imply that MDM2 has the 
most important role on p53 degradation and is not dispensable.  
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Figure 1.2: MDM2 mediated control of p53 stabilization.MDM2 mono-ubiquitinates 
p53 by binding to the transactivation domain of p53. This results in the nuclear export 
of p53 to the cytoplasm for poly-ubiquitination by MDM2 and p300 and subsequently 
degradation by 26S protesome. In the case of a cellular stress, such as DNA damage, 
either various kinases phosphorylate p53 to free it from MDM2 or HAUSP de-
ubiquitinates p53. These post-translational modifications stabilize and activate p53. 
 
 Another protein that is structurally related to MDM2 is MDMX (alternatively 
named MDM4). MDMX also has a RING domain however it is incapable of E3 ligase 
activity towards p53. Instead, it directly inhibits the transcriptional activity of p53 after 
binding to the transactivation domain of the protein 39. MDMX also hetero-oligomerizes 
with MDM2 through their RING domains and stabilizes MDM2 by inhibiting its self-
ubiquitination 40. In turn, MDM2 shuttles MDMX to and from the nucleus because 
MDMX lacks nuclear localization and export signals. Although not as major as MDM2, 
there are other ubiquitin ligases that contribute to the stability of p53. Among these, the 
most famous are Pirh2, Cop1 and p300/CBP  41. Both Pirh2 and Cop1 E3 ligases are 
able to ubiquitinate p53 independent of MDM2 function. p300/CBP is a cytoplasmic E4 
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ligase which polyubiquitinates p53 and as a result directs it to 26S proteosomal 
degredation 42. 
 
In response to a wide variety of cellular stresses, p53 is phosphorylated at many 
different residues, among which the most important are Ser15 and Ser20, by ATM, 
ATR, DNA-PK and Chk1-2 kinases, rescuing p53 from MDM2 mediated ubiquitination 
and therefore stabilizing p53 43. Beside the post-translational modifications on p53, 
some phosphorylation on MDM2 and MDMX also occur, mostly by ATM and also 
other kinases, to impair their interaction with p53 and to promote their ubiquitination 
and nuclear export 44,45. The acetylation of p53 on the C-terminal lysine residues 
inhibits the ubiquitination process because these sites compete for acetylation and 
ubiquitination 46. p300/CBP plays a dual role in p53 stability and activity; while it poly-
ubiquitinates the mono-ubiquitinated p53 to direct it for proteosomal degradation, it also 
acetylates the p53 at the C-terminal ubiquitination residues to ensure that MDM2 cannot 
function on p53, therefore stabilizing p53. One way of stabilizing p53 is rescuing it 
from the ubiquitination activity of MDM2; however, there are other ways of stabilizing 
it, which is removing of the ubiquitin modifications, called de-ubiquitination. HAUSP is 
a p53-interacting protein which specifically targets the ubiquitin moieties on p53 upon 
induced-cellular stress and removes them by its protease activity 47. On the other hand, 
under unstressed conditions, HAUSP de-ubiquitinates MDM2 and MDMX and protects 
them from degradation, therefore contributes to the establishing of the delicate balance 
of p53 levels 48. 
 
 
 
1.1.4. Induction of p53 
 
 
Cellular stress signals stabilize and activate p53 in a context dependent manner 
(Figure 1.3). This is because depending on the type and the mechanism of the stress 
signal, different pathways are utilized and therefore p53 is activated via different post-
translational modifications or co-activators. DNA damage is the most effective and 
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most studied way of inducing p53. Ultraviolet light (UV), ionizing radiation, and 
genotoxic drugs are also capable of stabilizing p53 49,50. Upon DNA damage, ATM and 
ATR along with other kinases effectively phosphorylate p53 to inhibit its interactions 
with MDM2 and MDMX 45. On the other hand, these kinases also phosphorylate 
MDM2 and MDMX, marking them for degradation 48. p53 is readily induced by 
activated oncogenes. This is mainly due to the 
 
 
Figure 1.3: Induction and response of p53. Cellular stress induces p53 to be post-
translationally modified and to interact with other partners to drive a cellular response. 
 
functions of p14ARF (ARF). ARF blocks the interaction between MDM2 and p53 by 
binding to MDM2, allowing p53 to accumulate 51. ARF is a perfect example of 
understanding that every stress signal has its own pathway to induce p53. This is 
because ARF is incapable of activating p53 in response to DNA damage 52. Dysfunction 
of ribosome is also a stress inducer for eukaryotic cells. Proteins (L5, L11, and L23) 
that are part of the ribosome itself are able to inhibit MDM2 by binding to it 53–55. Solid 
tumors experience hypoxic conditions towards the inner parts of the tumor due to 
insufficient formation of blood vessels, a process called angiogenesis. p53 is stabilized 
by HIF-1α by their interaction under hypoxia 56. HIF-1α is also noteworthy because 
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HIF-1α driven p53 induces a different set of target genes than induced by DNA damage 
driven p53 57. Besides these stresses, others such as nutrient deprivation, oxidative 
stress, and telomere attrition can also stabilize p53 58–60. 
 
 
 
1.1.5. p53 Responses in Tumor Suppression 
 
 
p53 is a very potent tumor suppressor protein that maintains the stability of cellular 
health and prevents tumorigenesis. Insult to cellular health causes stress for the cell 
resulting in p53 accumulation. The type and extent of the insult as well as the origin of 
the cell are the criteria that determines the mechanism of p53 accumulation and the 
specific outcome of this activation. Therefore, the p53 response is highly context 
dependent 61. Specific combinations of various posttranslational modifications and 
recruited co-factors (either repressors or activators) play roles in context dependent 
responses. Among the responses of p53 that are important for tumorigenesis are cell-
cycle arrest and senescence, DNA repair and recombination, and when the stress is too 
excessive for the cell, the autophagy and the apoptosis pathways are utilized. It is clear 
that the roles of p53 on controlling tumorigenesis are through keeping cell growth in 
control.  
 
Upon cellular stress, such as DNA damage, p53 induces cell-cycle arrest in the G1/S 
and the G2/M phases of the cell cycle, allowing cells to repair damaged DNA or cellular 
compartments before progressing into the next phase of the cell cycle 62 (Figure 1.4). It 
is pivotal for the cells to have such a control mechanism in cell cycle progression 
because an accumulated damage if not repaired has high risk of inducing tumorigenesis. 
Upon stabilization, p53 induces G1 arrest by transactivating the expression of p21 
protein, a cyclin-dependent kinase (CDK) inhibitor, from the CDKN1A gene locus 63. 
p21, in turn, inhibits the kinase activity of CDK2, which normally initiates S-phase  
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Figure 1.4: Cell-cycle regulation by p53. Cellular stress, such as DNA damage, induces 
p53 dependent-cell cycle arrest. P53 transactivates p21 and p21 inhibits CDK2 to arrest 
cells at G1/S phase transition. P53 also transactivates GADD45 and 13-3-3σ, which are 
inhibitors of CDK1. They arrest cells at G2/M transition. 
 
entry by phosphorylating Rb 64. p53 also transactivates GADD45 and 13-3-3σ in order 
to induce G2 arrest 65,66. GADD45 and 13-3-3σ work in synchrony in inhibiting mitosis 
inducing kinase CDK1, either by preventing complex formation of CDK1 with its 
targets or by exporting CDK1 out of the nucleus 65,66. The mechanism of the cellular 
stress determines in which cell cycle check point the cells will arrest. Instead of a 
reversible cell-cycle arrest, p53 can also induce senescence, which is characterized by 
permanent cell cycle-arrest 67. 
 
 When the degree of the insult to cellular health is too severe and irreversible, 
p53 initiates   apoptotic pathways   (Figure 1.5).   While nuclear   p53  induces   
apoptosis using its transcription-dependent activities; cytosolic p53 also contributes to 
apoptosis through a transcription-independent fashion 68. p53 transactivates or 
transrepresses a wide variety of genes for induction of apoptosis, such as BAX, BAD, 
BAK, BID, NOXA, PUMA, BCL-2, BCL-XL, and SURVIVIN. PUMA is one of the key 
mediators of apoptosis. It is rapidly upregulated upon DNA damage and initiates 
apoptosis  by   localizing to the  mitochondria 69. Cytosolic   p53 also localizes to the 
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Figure 1.5: Induction of apoptosis by p53. p53 is able to induce apoptosis through 
transcription-dependent and –independent functions. Stabilized and activated p53 
transactivates pro-apoptotic genes, as well as it goes directly to the mitochondria to 
initiate MOMP. 
 
mitochondria in order to trigger mitochondrial outer membrane permeabilization 
(MOMP) 68. MOMP is followed by a series of downstream cascade of events that 
finally lead to the apoptotic death of the cell.  
 
 
 
 
1.2. POZ-, AT-Hook, and Zinc Finger-Containing Protein PATZ1 
 
 
 
1.2.1. The BTB-ZF Transcription Factors 
 
 
PATZ1 (POZ (BTB) and AT hook containing zinc finger 1, also known as ZSG, 
MAZR, PATZ, RIAZ, ZBTB19, ZNF278, dJ400N23) belongs to a class of transcription 
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factors that have an N-terminal BTB/POK domain for protein-protein interaction and a 
C-terminal zinc finger motif containing DNA binding domain. BTB stands for Broad-
complex, Tramtrack, and Bric-à-brac that are the genes cloned from Drosophila 
melanogaster mutants 70–72. Another name for BTB is POZ (Poxviruses and Zinc-finger 
(POZ) and Krüppel). BTB and ZF (zinc finger) are protein domains that are found in 
eukaryotes and viruses 73. The BTB domain is about 120 amino acids long and it is used 
for protein-protein interactions and oligomerization 74. The ZF motif binds to specific 
DNA sequences and generally consists of two cysteines followed by two histidines 
(C2H2) 
75. The human genome encodes 156 BTB domain-containing proteins and 49 of 
them have a variable number of ZF motifs, and a couple of them also have an AT-hook 
motif, which binds to the minor groove of specific AT-rich sequences 76,77.  
 
BTB-ZF transcription factors use their BTB domain to homo- or hetero-dimerize 
and to interact with transcription co-factors. Among such factors are SIN3A, SMRT, 
NCOR1, and p300 78,79. These co-factors might be transcriptional activators as well as 
repressors and they can also recruit other histone modifying enzymes, such as HDAC, 
causing epigenetic changes. Therefore, the role of the BTB-ZF proteins on the 
transcription is context dependent and depends on the co-factors that they associate with 
(Figure 1.6). BTB-ZF proteins function in many distinct biological processes including 
the development of lymphocytes, stem cell biology, fertility, skeletal morphogenesis, 
neurological development, and tumorigenesis. 
 
 
Figure 1.6: Epigenetic changes by BTB-ZF proteins. BTB-ZF proteins recognize their 
specific response elements on the genome through their ZF motifs and bind to co-
factors from their BTB domain. Co-factors recruit histone-modifying enzymes to induce 
epigenetic changes for heterochromatin (depicted as tight DNA structure) or 
euchromatin (depicted as relaxed DNA structure) confirmations.  
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1.2.2. The Role of The BTB-ZF Transcription Factors in Tumorigenesis 
 
 
Apart from their regular functions in a healthy living cell, several BTB-ZF proteins 
are also associated with DNA damage response and cell cycle regulation during 
tumorigenesis. These functions were identified as chromosomal translocations in 
tumors. Some examples to the BTB-ZF proteins that play role in tumorigenesis are 
PLZF, BCL6, HIC-1, NAC-1, and ZBTB7. PLZF and BCL6 are known to promote 
tumorigenesis by translocation. The translocation of PLZF gene into RAR-α gene causes 
acute promyelocytic leukemia 80. The resulting PLZF-RAR-α fusion protein gains novel 
functions by combining the co-factor recruitment capacity of PLZF and the 
transcriptional activity of RAR-α. Upon translocation, the regular targets of RAR-α 
involved in DNA repair, cell cycle and apoptosis change their expression patterns. This 
triggers leukemia transformation by inhibiting the activity of p53 81. On the other hand, 
wild type PLZF represses the transcription of the c-myc oncogene. Therefore, by itself, 
it is also associated with tumor suppression 82. Another BTB-ZF that is identified 
through chromosomal translocation is BCL6. BCL6 is found to translocate with many 
genes, however, these events usually do not create a novel fusion protein because the 
exons coding for BCL6 protein remain undisturbed after the translocation events and it 
is rather the promoter that is substituted. This does not affect the production of the wild 
type protein but it causes a deregulated expression pattern 83. The translocation of BCL6 
results in non-Hodgkin’s lymphomas, like diffuse large B cell lymphoma 84. Actively 
transcribed BCL6 causes transcriptional repression of the tumor suppressor p53, the 
DNA damage sensor ATR and the cell cycle mediator CDKN1A (p21) 83,85,86. 
 
 Other BTB-ZF proteins such as HIC-1 and ZBTB7 promote tumorigenesis by 
upregulating cell cycle regulators. The HIC-1 gene is located in close proximity to the 
TP53 gene and its expression is induced by p53 88. HIC-1 BTB-ZF protein is in a 
positive feedback loop for p53 because HIC-1 interacts with SIRT1 and this complex 
suppresses the transcription of the SIRT1 gene, whose protein product deacetylates p53 
to mark it for degradation 89. During most types of tumorigenesis, the HIC-1 locus is 
either hyper-methylated or lost from the genome completely. This causes upregulation 
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Figure 1.7: BTB-ZF proteins in p53 regulation. Several BTB-ZF proteins are linked to 
p53 regulation, directly or indirectly. ZBTB7 down regulates CDKN2A gene, which 
expresses ARF, an important protein that regulates the stability of p53. p53 induces 
HIC-1 expression, which in turn suppresses SIRT1 gene expression, whose product, 
SIRT1 protein, deacetylates and inactivates p53. BCL6 represses TP53 gene. NAC-1 
causes increased levels of p53 protein 87. When PLZF translocates into RAR-α gene, the 
fusion protein inhibits p53 protein.  
 
of SIRT1 and as a result, degradation of p53. These indications suggest that HIC-1 is a 
candidate tumor suppressor protein. ZBTB7 is identified as a master regulator of 
oncogenesis due to its critical role in suppressing ARF expression 90. In an oncogene 
transformed cell, ARF is promptly upregulated to activate p53 and apoptosis. However, 
ZBTB7 is overexpressed in most human cancers and this is a marker for the progression 
of the disease and outcome of the treatment 91. Recent studies are directed to target 
ZBTB7 downregulation in oncogene induced tumorigenesis. These findings indicate 
that BTB-ZF proteins play important roles during normal biological processes and also 
during tumorigenesis. Moreover, the functions of BTB-ZF proteins might sometimes 
coincide with the p53 pathway (Figure 1.7). This is mostly due to their ability to interact 
with histone modifying enzymes such as histone acetyltransferases (HDAC) and histone 
deacetylases (HATs) and a wide variety of co-factors.  
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1.2.3. PATZ1 
 
 
PATZ1 belongs to the BTB-ZF containing transcription factor family. Although 
there is not a comprehensive study that covers the function of PATZ1 in tumorigenesis, 
there are a handful of data that indicate that PATZ1 is involved in tumor development. 
PATZ1 was first discovered as an interaction partner of BACH2, a BTB-ZF family 
member, through their BTB domains,  and it is found to be expressed in brain, thymus, 
fetal liver, and bone marrow, and especially in B-cell lines in different stages of 
development 92. PATZ1 was also found to interact with RNF4, a ring finger protein 
family member, through its AT-hook domain 93. RNF4 plays an important role for 
androgen receptor activation, however, interaction of RNF4 with PATZ1 changes the 
activation to repression 94. This shows that PATZ1 has developmental roles since 
androgen mechanism is critical for the development of the male reproductive system 
and for normal and tumorigenic prostate 95. Indeed, PATZ1 knock-out male mice have 
smaller testes with a very few spermatocytes due to increased spontaneous apoptosis 96.  
In the same study, in human testicular cancer tissues, PATZ1 was found to be 
upregulated; however, it was mislocalized to the cytoplasm. Also the shRNA mediated 
downregulation of PATZ1 in glioma cells (brain and central nervous system tumors 
derived from glial cells) makes them vulnerable to apoptotic stimuli 97. 
 
Early embryonic expression of PATZ1 has a vital importance for mice because 
PATZ1 knockout mice are born at a non-Mendelian frequency and are smaller in size 
98,99. Recently, it was found that PATZ1 plays a key role for the maintenance of 
pluripotency of mouse embryonic stem cells (mESCs), in which it positively controls 
the expression of the Pou5fl (Oct4) and Nanog genes that are master pluripotency 
regulators 100. PATZ1 is also important for controlled and normal development of T 
lymphocytes, as it negatively regulates the Cd8 gene expression during the Double 
Negative (DN) stage of T lymphocyte development by recruiting chromatin modifying 
co-factors, such as N-CoR, to the enhancer of Cd8 101. However, during the Double 
Positive (DP) stage, PATZ1 represses the Thpok gene by directly binding to its 
enhancer, directing these cell to the CD8+CD4- linage 99. These data suggest that the 
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PATZ1 transcription factor can control gene expression in more than one way 
depending on whether it acts alone or in complex with other co-factors. Similarly, 
PATZ1 was shown to  activate or repress the c-myc promoter; these conflicting results 
likely arise from the activity of the different alternatively spliced isoforms examined in 
these studies 92,93. In the later study, the BTB domain of PATZ1 was required for the 
transcription repressor activity of PATZ1. This suggests that PATZ1 recruits other co-
factors to the promoter using its BTB domain.  
 
A link between p53 and PATZ1 was first established in human endothelial cells. 
Overexpression of PATZ1 in old and senescent fibroblasts resulted in a reversed 
senescent phenotype, whereas shRNA mediated knock-down of PATZ1 in young and 
proliferating fibroblasts accelerated premature senescence 102. However, this premature 
senescence in cells that do no express PATZ1 is rescued by shRNA mediated knock-
down of p53. This study concluded that PATZ1 regulates senescence in fibroblast 
through a p53 dependent pathway. In a recent study, PATZ1 was shown to interact with 
p53 and modulate the transcriptional activity of p53 103. As many other BTB-ZF family 
members, PATZ1 was also identified in a chromosomal translocation event. 
Translocation of the BTB domain of PATZ1 into the zinc finger domain of EWS causes 
Ewing's sarcoma, which is characterized by a highly aggressive bone and soft tissue 
tumor usually seen in children 104. PATZ1 and another BTB-ZF protein BCL6 are found 
to be interacting from their BTB domains 105. This interaction results in the 
downregulation of BCL6 expression. In the absence of PATZ1, mice develop BCL6-
expressing lymphomas and die earlier compared to their wild type littermates, hence, 
PATZ1 has a tumor suppressor activity. Moreover, PATZ1 is upregulated in a series of 
colorectal cancer tissue, human breast cancer cell lines as well as different cancer cell 
lines 106,107. It is associated with cell growth, as its overexpression resulted in increased 
cell proliferation in the colon cancer cell line SW1116, and downregulation resulted in 
suppressed proliferation 106. For this reason, PATZ1 is predicted to be a possible proto-
oncogene. These findings indicate that PATZ1 is indeed a factor involved in tumor 
development; however, it is still unclear if PATZ1 is a proto-oncogene or a tumor 
suppressor. This remains to be elucidated.  
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2. AIM OF THE STUDY 
 
 
 
 
BTB-ZF family transcription factors function in many distinct biological processes 
including the development of lymphocytes, stem cell biology, fertility, skeletal 
morphogenesis, neurological development, and tumorigenesis. These proteins can 
hetero-dimerize with each other to switch on or enhance their transcriptional activities. 
They also interact with other distinct transcription factors and recruit chromatin 
remodeling co-factors to the DNA, such as histone acetyltransferases and histone 
deacetylasetheses. These interactions mediate epigenetic modifications and enable or 
disable gene transcription. The roles of BTB-ZF transcription factors in many different 
and important biological processes make them crucial factors during tumorigenesis. 
Indeed, many BTB-ZF proteins were identified as modulators of the p53 pathway. The 
p53 tumor suppressor protein is found to play a major role in many cancer types and 
therefore any factor that controls p53 activity has vital importance for human health.  
 
We identified the BTB-ZF family transcription factor PATZ1 as a regulator of the 
p53 dependent DNA damage response. PATZ1 is known to be misexpressed in various 
human cancers and its absence favors lymphomagenesis in mice and the translocation of 
the PATZ1 gene is associated with sarcoma development in humans. We aimed to 
elucidate the molecular mechanisms utilized by PATZ1 in tumorigenesis. We found that 
PATZ1 was lost upon DNA damage induction. PATZ1 inhibited the transcriptional 
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activity of p53 in reporter assays. To generalize the finding that PATZ1 regulates p53 
activity, we performed genome wide expression analysis in PATZ1 deficient and 
sufficient cells that were treated with a DNA damage inducing chemical. We identified 
biological processes in which PATZ1 mediated p53 and DNA damage related functions. 
In this study, we characterize the transcription factor PATZ1 as a new mediator of the 
p53 mediated DNA damage response.  
 
 
 
  
19 
 
 
 
 
 
 
 
3. MATERIALS AND METHODS 
 
 
 
 
3.1. Materials 
 
 
 
3.1.1. Chemicals 
 
 
All the chemicals used in this thesis are listed in Appendix A. 
 
 
 
3.1.2. Equipment 
 
 
All the equipment used in this thesis is listed in Appendix B. 
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3.1.3. Buffers and Solutions 
 
 
Standard buffers and solutions used in the project were prepared according to the 
protocols in Sambrook et al., 2001. 
 
Agarose Gel: For 100 ml 1% w/v gel, 1 g of agarose powder was dissolved in 100 
ml 0.5X TBE buffer by heating. 0.01% (v/v) ethidium bromide was added to the 
solution. 
Calcium Chloride (CaCl2) Solution: 60mM CaCl2 (diluted from 1M stock), 15% 
Glycerol, and 10mM PIPES (pH 7.00) were mixed and the solution was filter-sterilized 
and stored at +4°C. 
Blocking Buffer: For 10ml, 0.5 g skim milk powder was dissolved in 10 ml PBS. 
FACS Buffer: For 500ml 1X solution, 2.5 g bovine serum albumin (BSA) and 0.5 
g sodium azide were mixed in 500 ml 1X PBS and the solution was kept at -20°C. 
HEPES-buffered saline (HBS): For 100 ml 2X solution 0.8 g NaCl, 0.027 g 
Na2HPO4.2H2O and 1.2 g HEPES were dissolved in 90 ml of ddH2O. pH was adjusted 
to 7.05 with 0.5 M NaOH and the solution was completed to 100 ml with distilled 
water. The buffer was filter-sterilized and stored at -20°C. 
PBS-Tween20 (PBST) Solution: For 1 L 1X solution, 0.5 mL Tween20 was added 
in 1 L 1X PBS. 
Phosphate-buffered saline (PBS): For 200 ml 1X solution, 1 tablet of PBS (Sigma 
P4417) was dissolved in 200 ml ddH2O and the solution was filter-sterilized. 
Polyethylenamine (PEI) Solution: For 1 mg/ml solution, 100 mg polyethylenamine 
powder was dissolved in 100 ml ddH2O and the pH was adjusted to 7.0 with HCl. The 
solution was filter sterilized and kept at -20°C. 
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Protein Loading Buffer: Commercial buffer (Fermentas #R0891) that includes 5X 
loadig dye (0.313 M Tris HCl (pH 6.8 at 25°C), 10% SDS, 0.05% bromophenol blue, 
50% glycerol) and 20X reducing agent (2 M DTT) were mixed. 
SDS Seperation Gel: For 10ml 13% gel, 2.5 ml Tris (1.5M pH 8.8), 3 ml H2O, 
4.34 ml Acryl: Bisacryl (30%), 100 μl 10% SDS, 100 μl 10% APS, and 10 μl TEMED 
were mixed. 
SDS Running Buffer: For 1 L 10X stock solution, 30.3 g Tris base, 144 g Glycine, 
and 10 g SDS were dissolved in 1L ddH2O. 
SDS Stacking Gel: For 5 ml 4% gel, 1.25 ml Tris (0.5 M pH 6.8), 2.70 ml H2O, 1 
ml Acryl: Bisacryl (30%), 50 μl 10% SDS, 15 μl 10% APS, and 7.5 μl TEMED were 
mixed. 
Transfer Buffer: For 1 L 10X stock solution, 14.5 g Tris and 72 g Glycine were 
dissolved in 1 L ddH2O. Final pH was adjusted to 8.3.  
Transfer Buffer: For 800 ml 1X, 80 ml 10X Transfer Buffer, 160 ml methanol, and 
560 ml ddH20 were mixed. 
Tris-Borate-EDTA (TBE) Buffer: For 1 L 10X stock solution, 104 g Tris-base, 55 
g boric acid, and 40 ml 0.5M EDTA (pH 8.0) were dissolved in 1 L of ddH2O. The 
solution is kept at room temperature. 
 
 
 
3.1.4. Growth Media 
 
 
Luria Broth (LB): For 1 L 1X LB media, 20 g LB powder was dissolved in 1 L 
ddH2O and then autoclaved at 121°C for 15 minutes. For selection, kanamycin at a final 
concentration of 50 μg/ml or ampicillin at a final concentration of 100 μg/ml was added 
to liquid medium just before use. 
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LB-Agar: For 1 L 1X agar medium, 20 g LB powder and 15 g bacterial agar 
powder were dissolved in 1 L ddH2O and then autoclaved at 121°C for 15 minutes. 
Autoclaved medium was poured onto sterile Petri dishes after cooling down to 50°C. 
For selection, kanamycin at a final concentration of 50 μg/ml or ampicillin at a final 
concentration of 100 μg/ml was added to the medium before pouring onto petri dishes. 
Sterile solid agar plates were kept at 4°C. 
DMEM: HEK293T, NIH3T3, HeLa, Phoenix, HCT116, HCT116p53-/-, U2OS, 
and H1299 cell lines and primary MEFs were maintained in filter-sterilized DMEM that 
is supplemented with 10% heat-inactivated fetal bovine serum, 2mM L-Glutamine, 100 
unit/ml penicillin and 100 unit/ml streptomycin. 
RPMI: 3B4.15, VL3.3M2, EL4, EL4-Ova, AKR1, and RLM11 cell lines and 
primary CD8+CD4- thymocyte were maintained in filter- sterilized RPMI1640 that is 
supplemented with 10% heat-inactivated fetal bovine serum, 2mM L-Glutamine, 100 
unit/ml penicillin, 100 unit/ml streptomycin, 1X MEM vitamins, 1X non-essential 
amino acids and 50µM 2-mercaptoethanol.  
Freezing medium: All the cell lines were frozen in heat-inactivated fetal bovine 
serum containing 10% DMSO (v/v). 
 
 
 
3.1.5. Commercial Molecular Biology Kits 
 
 
 QIAGEN Plasmid Midi Kit, 12145, QIAGEN 
 QIAGEN Plasmid Maxi Kit, 12163, QIAGEN 
 Qiaprep Spin Miniprep Kit, QIAGEN 
 Qiaquick Gel Extraction Kit, 28706, QIAGEN 
 Qiaquick PCR Purification Kit,28106, QIAGEN 
 RevertAid First Strand cDNA Synthesis Kit, K1622, FERMENTAS  
 SuperScript Double-Stranded cDNA Synthesis Kit, 11917-020, INVITROGEN 
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 Leukocyte Alkaline Phosphatase Kit, 86R-1kt, SIGMA-ALDRICH 
 
 
 
3.1.6. Enzymes 
 
 
All the restriction enzymes, DNA modifying enzymes and polymerases and their 
corresponding buffers used in this study were from either Fermentas or NEB.  
 
 
 
3.1.7. Bacterial Strains 
 
 
Escherichia coli DH-5α (F- endA1 glnV44 thi-1 relA1 gyrA96 deoR nupG 
lacZdeltaM15 hsdR17) competent cells were used for bacterial transformation of 
gerenal plasmid DNAs. HB101 strain was used for bacterial transformation of retroviral 
plasmid DNAs. 
 
 
3.1.8. Mammalian Cell Lines 
 
 
HEK293T: Derivative of human embryonic kidney 293 (HEK293) cell line that 
stably express the large T antigen of SV40 virus (ATCC: CRL-1573™). 
NIH3T3: Mouse embryonic fibroblast cell line (ATCC: CRL-1658™). 
24 
 
HeLa: Human epithelial carcinoma cell line (ATCC: CCL-2™). 
Phoenix-Eco: Second-generation retrovirus producer cell line based on HEK293T 
cell line that express gag-pol-env proteins for the generation of helper free ecotropic 
retroviruses 108. 
HCT116 and HCT116p53-/-: Human colorectal carcinoma cell line and its p53-
null derivative (ATCC CCL-247™) 
U2OS: Human osteosarcoma cell line (ATCC HTB-96™) 
H1299: Human non-small cell lung cancer cell line (ATCC CRL-5803™) 
3B4.15: CD4+CD8- murine T cell hybridoma cell line that is specific to pigeon 
cytochrome C in association with I-Ek  109. 
VL3.3M2: CD4+CD8+ murine thymic lymphoma cell line 110. 
EL4 and EL4-Ova: CD4+CD8- murine lymphoma cell line and its chicken 
ovalbumin (OVA) overexpressing derivative (ATCC TIB-39™ and ATCC CRL-
2113™, respectively). 
AKR1: CD44- murine T-lymphoma cell line 111. 
RLM11: Radiation-induced CD4+CD8- murine thymoma cell line 112. 
 
 
3.1.9. Plasmids and Primers 
 
 
The plasmids and the primers used in this thesis are listed in Table 3.1 and Table 
3.2, respectively. 
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PLASMID NAME 
 
 
PURPOSE OF USE 
 
 
SOURCE 
 
PCMV-HA Cloning Clontech 
pCMV-myc Cloning Clontech 
pCMV-HA-PATZ1 Mammalian Expression Lab Construct 
pCMV-HA-PATZ1Alt Mammalian Expression Lab Construct 
pCMV-myc-PATZ1 Mammalian Expression Lab Construct 
pCMV-myc-PATZ1Alt Mammalian Expression Lab Construct 
pFlag-CMV4 Cloning Clontech 
pFlag-CMV4-p53 Mammalian Expression 
Ozoren Lab, Bogazici 
University 
SV40-p53α Mammalian Expression 
Bourdon Lab, Dundee 
University 
SV40-p53β Mammalian Expression 
Bourdon Lab, Dundee 
University 
pBABE-Puro Cloning Addgene: #1764 
pBABE-Puro-PATZ1 Mammalian Expression Lab Construct 
pMIG-GFP/NEO Cloning 
Ellmeier Lab, Medical 
University of Vienna 
pMIG-GFP/NEO-PATZ1 Mammalian Expression Lab Construct 
pMIGII-mCherry Cloning Lab Construct 
pMIGII-mCherry-PATZ1 Mammalian Expression Lab Construct 
pMIGII-mCherry-PATZ1Alt Mammalian Expression Lab Construct 
pMIGII-mCherry-PATZ1-R372G Mammalian Expression Lab Construct 
pMIGII-mCherry-PATZ1-R403G Mammalian Expression Lab Construct 
pMIGII-mCherry-PATZ1-R424G Mammalian Expression Lab Construct 
pCMV-HA-PATZ1-R372G Mammalian Expression Lab Construct 
pCMV-HA-PATZ1-R394G Mammalian Expression Lab Construct 
pCMV-HA-PATZ1-R403G Mammalian Expression Lab Construct 
pCMV-HA-PATZ1-R424G Mammalian Expression Lab Construct 
pCMV-HA-PATZ1-R456G Mammalian Expression Lab Construct 
pCMV-HA-PATZ1-N495Y Mammalian Expression Lab Construct 
pCMV-HA-PATZ1-D521Y Mammalian Expression Lab Construct 
pCMV-HA-PATZ1-
D521Y/D527Y 
Mammalian Expression Lab Construct 
LMP-sh29 (shPATZ1) 
Knocking Down Mouse 
PATZ1 Expression 
Lab Construct 
LMP-sh62 
Knocking Down Mouse 
PATZ1 Expression 
Lab Construct 
pcDNA-GFP Mammalian Expression Lab Construct 
pG13 Luciferase Reporter Addgene: #16442 
mG15 Luciferase Reporter Addgene: #16443 
p21-LUC Luciferase Reporter Addgene: #16451 
Puma-LUC Luciferase Reporter Addgene: 16591 
pRLSV40 
Luciferase 
Normalization 
Promega 
pCAG-T7 Cloning 
Starker Lab, 
University of 
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Minnesota 
pCAG-T7-hMAZR-TALENfwd 
Disrupting Human 
PATZ1 Gene 
Lab Construct 
pCAG-T7-hMAZR-TALENrev 
Disrupting Human 
PATZ1 Gene 
Lab Construct 
MSCV pGK eGFP 
Cre-mediated loxP 
recombination 
Ellmeier Lab, Medical 
University of Vienna 
MSCV pGK eGFP-CRE 
Cre-mediated loxP 
recombination 
Ellmeier Lab, Medical 
University of Vienna 
pIRES2eGFP Cloning Clontech 
pIRES2eGFP-mCAT Mammalian Expression Lab Construct 
Table 3.1: The list of the plasmids used in this thesis. Plasmid names, their purpose of 
uses and sources are given. 
 
 
PRIMER NAME 
 
 
SEQUENCE 
 
 
PURPOSE 
OF USE 
 
h_p21rt_fwd GCAGACCAGCATGACAGATTT p21 qPCR 
h_p21rt_rev GGATTAGGGCTTCCTCTTGGA p21 qPCR 
puma fwd ACCAGCCCAGCAGCACTTAG 
puma 
qPCR 
puma rev TCTTCTTGTCTCCGCCGCTC 
puma 
qPCR 
gapdh fwd TCCTGCACCACCAACTG gapdh fwd 
gapdh rev TCTGGGTGGCAGTGATG gapdh rev 
mouse e2f GCACACTTCTGAGCGACCTCACAAGTG 
semi q 
rtPCR 
mouse e3r TGCTGGAGTGTGCTGGACTCAGG 
semi q 
rtPCR 
mouse e6r TCAATCAGATCCTGATGTGAGCAT 
semi q 
rtPCR 
human e4f GGCCCAGCAACTTCTGCAGTATC 
semi q 
rtPCR 
human e6r TGAGAGGTCACCATAGGAGTCAGAG 
semi q 
rtPCR 
human e2f TCAAGCAGGTGCACACTTCTGAG 
semi q 
rtPCR 
human e3r TGGGACGACCTCCACAAAGC 
semi q 
rtPCR 
human e4f qPCR CAATGCTTCTTTTGCCACCC 
Patz 
degradatio
n qPCR 
human e4-6r qPCR ATTTCTGGCCTTCTCGGTTACA 
Patz 
degradatio
n qPCR 
F2 GGGTCTAGCCCTTTTTATTAGAGC mouse 
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Patz1 
genotyping 
R2 GAAGCTCTCGTCGCCTACTC 
mouse 
Patz1 
genotyping 
CreR2 GTTATGTTCTATTAAGGTCCAGTGACC 
mouse 
Patz1 
genotyping 
EBV-rev GTGGTTTGTCCAAACTCATC sequencing 
CMV-fwd CGCAAATGGGCGGTAGGCGTG sequencing 
Arg372Gly-Fwd TATACCATCTCAACGGGCATAAGCTTTCC 
PATZ1 
Arg372Gly 
mutation 
Arg372Gly-Rev CGTCACGAAAGATCTTGCCACAGATC 
PATZ1 
Arg372Gly 
mutation 
Arg403Gly-Fwd TCGTACCATGTGGGGTCCCATGATG 
PATZ1 
Arg403Gly 
mutation 
Arg403Gly-Rev CATTCGGTCTTTTCTCTTGAACCGCAG 
PATZ1 
Arg403Gly 
mutation 
Arg424Gly-Fwd GAAAGGTTTCTCCGGGCCAGATCACTTG 
PATZ1 
Arg424Gly 
mutation 
Arg424Gly-Rev CCACAGCTCTGGCAGATGTACGGTTTG 
PATZ1 
Arg424Gly 
mutation 
hMAZRtALENcontr
olFwd 
TGGCAGGCGCGTTTGCAG 
Human 
PATZ1 
genotyping 
after 
TALEN 
hMAZRtALENcontr
olRev 
GAAGCTCTCGTCGCCTACCC 
Human 
PATZ1 
genotyping 
after 
TALEN 
Table 3.2: The list of the primers used in this thesis. Primer names, their sequences, and 
their purpose of uses are given. 
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3.1.10. DNA and Protein Molecular Weight Markers 
 
 
DNA ladders and protein molecular weight markers used in this thesis are listed in 
Appendix C. 
 
 
 
3.1.11. DNA Sequencing 
 
 
Sequencing service was commercially provided by McLab, CA, USA. 
(http://www.mclab.com/). 
 
 
3.1.12. Software, Computer-Based Programs, and Websites 
 
 
The software and computer based programs used in this project are listed in Table 
3.3 
 
SOFTWARE, 
PROGRAM, 
WEBSITE NAME 
 
COMPANY/WEBSITE ADDRESS 
 
 
PURPOSE OF USE 
 
NCBI BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi 
Basic local alignment 
search tool 
FlowJo V10 Tree Star Inc. 
Viewing and 
analyzing flow 
cytometry data 
ImageJ http://imagej.nih.gov/ij/ 
Counting IPSC 
colonies 
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CLC Main 
Workbench 
CLC bio 
Constructing vector 
maps, restriction 
analysis, DNA 
sequencing analysis, 
DNA alignments, etc 
Ensembl Genome 
Browser 
http://www.ensembl.org/index.html 
Human and mouse 
genome 
LightCycler 480 SW 
1.5 
ROCHE 
Analysing qPCR 
results 
RTCA Software 2.0 ACEA Biosciences 
Real-time cell growth 
analysis 
DAVID 
Bioinformatics 
Resources 6.7 
NIAID, NIH 
Bioinformatics 
analysis of RNAseq 
data 
ANAIS http://anais.versailles.inra.fr/ 
Boinformatics 
analysis of 
NimbleGen arrays 
Cytoscape http://www.cytoscape.org/ 
Network data 
integration, analysis, 
and visualization 
GenePattern http://genepattern.broadinstitute.org/ 
Creating heatmaps for 
RNAseq data 
Table 3.3: The list of the software, programs and websites used in this thesis. Name of 
the software, programs, and websites, their producers/websites and purpose of uses are 
given. 
 
 
 
 
3.2. Methods 
 
 
 
3.2.1. Bacterial Cell Culture 
 
 
 Bacterial Culture Growth:  Escherichia coli (E. coli) DH5α strain was grown in 
Luria Broth (LB) or 2XLB (low salt), overnight at 37ºC, shaking at 250 rpm. For long-
term storage of bacterial cells, glycerol was added to the overnight grown culture to a 
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final concentration of 10% in 1 mL in a cryovial. Bacterial glycerol stocks were stored 
at -80°C. In order to obtain single colonies, bacteria were spread on LB/agar containing 
petri dishes using glass beads and incubated overnight at 37ºC without any shaking. All 
growth medium were supplemented with or without selective antibiotic prior to any 
application.  
 
 Preparation and Transformation of Competent Bacteria: A single colony of 
E.coli DH5α was picked from an LB/agar petri dish (incubated overnight without any 
antibiotic selection). The colony was inoculated in 50 mL LB without any selective 
antibiotics in a 200 mL flask and incubated at 37ºC overnight, shaking at 250 rpm. The 
next day, 4 mL from this overnight culture was diluted in 400 mL LB medium in a 2 L 
flask and incubated at 37ºC overnight, shaking at 250 rpm until the optical density (at 
590 nm) reached 0.375. The culture was then transferred into 50 ml polypropylene tubes 
(8 tubes in total) and incubated on ice for 10 min, followed by a centrifugation at 1600 g 
for 10 min at 4ºC. After centrifugation, each pellet was resuspended in 10 mL ice-cold 
CaCl2 solution and centrifuged at 1100 g for 5 min at 4ºC. The pellets were again 
resuspended in 10mL ice-cold CaCl2 solution and incubated on ice for 30 min. 
Following the final centrifugation at 1100 g for 10 min at 4ºC, this time the pellets were 
resuspended in 2mL ice-cold CaCl2 solution and pooled in a single polypropylene tube 
(16 ml bacterial solution in total). This solution was dispensed into 200µL aliquots into 
pre-chilled 1.5ml centrifuge tubes. Competent cells were frozen immediately in liquid 
nitrogen and then stored at -80ºC for later use. Transformation efficiency of the 
competent cells (typically 107-108 cfu/µg) was tested by pUC19 plasmid transformation, 
using different concentrations of the plasmid DNA.  
 
 Chemically competent cell was taken out from -80ºC and mixed with 100 pg of 
plasmid DNA. The cells were then incubated on ice for 30 min.  After the incubation 
period, the cells were heat shocked for 90 s at 42ºC and transferred back on ice for 60 s. 
800 µL of LB (without any antibiotics) was added on the cells and this culture was 
incubated for 45 min at 37ºC. After 45 min, the cells were spread with glass beads on 
LB/agar petri dishes containing appropriate antibiotic for selection. The plate was 
incubated overnight at 37ºC without any shaking.  
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 Plasmid DNA Isolation: Plasmid DNA isolation was performed using either the 
alkaline lysis protocol from Molecular Cloning: A Laboratory Manual (Sambrook et al) 
or Qiagen Mini-Midiprep Kits according to the manufacturer protocols. The 
concentration and purity of the DNA isolated were determined by using a UV- or a 
NanoDrop- spectrophotometer. 
 
 
 
3.2.2. Plasmid Construction 
 
 
 Polymerase Chain Reaction (PCR): Optimized PCR conditions are shown in 
Table 3.3. The thermal cycler conditions were as follows: initial denaturation at 95ºC 
for 5 min followed by 30 (or 35) cycles of denaturation step (at 95ºC, for 30 seconds), 
annealing step (at a temperature specific for every primer pair, for 30 seconds) and an 
extension step (at 72ºC, for 1 min for every 1 kilobase of DNA). These cycles were then 
followed by a final extension step at 72ºC for 10 min. 
PCR Reaction Volume Used Final Concentration 
Template DNA 1-10 µL 4pg/µL – 4ng/µL 
10X Pfu or Taq Polymerase 
Buffer (with MgCl2) 
2.5 µL 1X 
dNTP mix (10 mM each) 0.5 µL 0.2mM 
Forward Primer (10 µM) 2 µL 0.8µM 
Reverse Primer (10 µM) 2 µL 0.8µM 
Pfu or Taq Polymerase 
(2.5U/µL) 
0.125 µL 0.125 U/µL 
ddH2O Up to 25µL - 
Total 25µL - 
Table 3.4: Optimized PCR conditions 
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 Restriction Enzyme Digestion: Restriction enzyme digestion reactions were 
performed by mixing the required amount of DNA with the desired enzymes and their 
compatible buffers in 1.5 mL centrifuge tube, followed by incubation in a waterbath set 
to a temperature optimum for the enzymes for a duration of 2 hours. For diagnostic 
digestions 1µg of DNA was used. 10µg or more DNA was digested for gel extraction 
and cloning purposes. If the plasmid DNA was digested with a single restriction enzyme 
and was planned to be used in a ligation reaction, then the linear plasmid was 
dephosphorylated by calf intestinal alkaline phosphatase (CIAP) enzyme for an 
additional 45 min at 37ºC. 
 
 Agarose Gel Electrophoresis: PCR products, digestion reaction products and 
other DNA samples were separated and visualized by agarose gels. Gels were prepared 
by dissolving the required amount of agarose (ranging from 0.5 g to 3 g depending on 
the sizes of the DNA fragments in the samples) in 100mL 0.5X TBE. In order to fully 
dissolve the agarose, the mixture was heated in a microwave oven. The solution was 
then cooled down and 2µl of ethidium bromide was added. After mixing properly, the 
gel was cast in a gel apparatus and cooled down and solidified. DNA samples were 
mixed with DNA loading dye were loaded into the gel, which was run at 100V for 75 
min in 0.5X TBE and the bands were visualized using UV light on a Biorad Imager. 
Desired DNA bands were excised from the gel and extracted using a Qiagen Gel 
Extraction Kit according to the manufacturer protocol.  
 
 Ligation: Ligation reactions were performed by using T4 DNA Ligase, in 1:3, 
1:5 or 1:10 vector to insert ratio, using 50 ng of the plasmid DNA. Ligation reactions 
were incubated at 16ºC for overnight. The next day, the ligation mixture was 
transformed into chemically competent DH5α bacteria and plated onto antibiotic 
selective-LB/agar petri dishes and incubated at 37ºC. 
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3.2.3. Mammalian Cell Culture 
 
 
 Maintenance of Cell Lines: The 3B4.15, VL3.3M2, EL4, EL4-Ova, AKR1, and 
RLM11 cell lines and primary CD8+CD4- thymocytes were maintained in RPMI1640 
medium in tissue culture flasks in an incubator set to 37oC with 5%CO2. Cells were 
splitted into pre-warmed, fresh medium with a ratio of 1:20 once in two or three days. 
HEK293T, NIH3T3, HeLa, Phoenix, HCT116, HCT116p53-/-, U2OS, and H1299 cell 
lines and primary MEFs were maintained in DMEM medium in tissue culture plates in 
an incubator set to 37oC with 5%CO2. When the confluency of the cells reached over 
80%, the cells were split into pre-warmed, fresh medium with a ratio of 1:10. In order to 
freeze cells for later use, cells at the exponential growth phase were resuspended in ice-
cold freezing medium and transferred to cryovials. Tubes were stored at -80°C for at 
least 24 h and then transferred to liquid nitrogen tank for long- term storage. After 
thawing the cells, they were immediately washed with growth medium to remove any 
residual DMSO. 
 
 Transient Transfection of Cell Lines Using Polyethylenimine (PEI): One day 
before the transfection, 1-3 x 106 cells were split onto 10 cm tissue culture plates. On 
the day of the transfection, 10 µg of plasmid DNA was mixed in 1 mL serum-free 
DMEM in a sterile micro centrifuge tube. PEI (1µg/µL) was added to the DNA-DMEM 
mix at a 3:1 ratio of PEI (µg) to total plasmid DNA (µg) and mixed immediately by 
vortexing. After 15 minutes of incubation at room temperature, the mixture was added 
drop wise on the cells.  
 
 Retroviral Infection: In order to produce retrovirus, the packaging cell line 
HEK293-Phoenix-Eco was transfected by the PEI method using 12 µg retroviral 
plasmid DNA and 3µg of packaging plasmid pCL-Eco. 48 hours after the transfections, 
supernatants of the cells were collected and filtered through 0.45nm filters. Polybrene 
(at a final concentration 8 µg/ml) was added to the filtered supernatant that contains the 
virus. Murine cells to be infected were split one day before the infection, so they would 
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be 60-80% confluent on the day of infection. The viral supernatant (with polybrene 
added) was used to infect the target murine cells. The growth medium of the cells were 
replaced the viral supernatant and the cells were returned to their incubators for 3 h. 
Then, the viral supernatant was discarded and fresh medium was added onto the cells. 
The cells were returned to their incubators for 24 h. The next day, a second infection 
was performed using the identical procedure. In order to infect human cell lines with 
ecotropic retrovirus, cells were pseudotyped by first transfecting them with the 
pIRES2eGFP-mCAT (mouse cationic amino acid transporter) plasmid 24 h prior to the 
first infection. For stable infections, 48 h after the second infection, the growth medium 
of the cells were supplemented with an appropriate antibiotic (typically puromycin at 
1µg/ml concentration). 
 
 Cell Lysis, SDS Gel, Transfer and Western-Blot: Cells were harvested from 
their cell culture plates either using trypsin or a cell scraper. Cells were centrifuged at 
1000 rpm for 5 min and the supernatant was discarded. The cells were washed once 
with 1X PBS and the pelleted again. The pellet was dissolved in an appropriate amount 
of protein loading buffer and the mixture was boiled at 95ºC for 10 min. The lysates 
were either kept at -80ºC for later use or used immediately. The SDS gels used in this 
project had a 10% separating part and a 4% stacking part. After the samples were loaded 
into the SDS gels, the gels were run with 1X running buffer at 100 V (constant voltage) 
for 1.5 - 2 h using a BIORAD Mini Protean Tetra Cell. After running, the gels were 
transferred to 0.45µm PVDF membranes (Thermo Scientific) in 1X transfer buffer at 
250 mA (constant current) for 1.5 h at 4oC using BIORAD Mini Trans-blot. Membranes 
were then blocked in 10 mL PBST - milk at room temperature for 1 hour with constant 
shaking. Primary antibody incubations were done overnight at 4oC and secondary 
antibody incubations were done for 1 hour at room temperature. After every incubation, 
membranes were washed with PBST 3 times for 10 min each. After the final washing 
step, the membranes were incubated with an enhanced chemiluminescent substrate for 5 
min at room temperature in the dark room and exposed to X-Ray films (Fuji). 
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3.2.4. RNA-Sequencing and Microarray 
 
 
 RNA-Sequencing: PATZ1 knockout or WT MEFs were prepared from mice 
embryos at day 13.5. Early passage MEFs were either untreated or treated with 1µM 
doxorubicin for 8 hours. Total RNA was extracted, polyA selected and triplicate 
samples were sequenced at Beijing Genomics Institute on an Illumina HiSeq 2000 
sequencing machine and analyzed using the R library DEseq. Differentially expressed 
genes (DEGs) were obtained based on the following criteria: fold-change > 2 and FDR 
value < 0.001. To identify biological processes regulated by PATZ1, DAVID analysis 
was performed for gene ontology (GO) terms. P-values are calculated by DAVID and 
GO terms that have smaller than 0.01 P-values are listed as significant.  
 
 Microarray: Early passage MEFs were either untreated or treated with 1µM 
doxorubicin for 24 hours. Total RNA was extracted using TriReagent (Sigma). Double-
stranded cDNA was generated using a Super- Script cDNA Synthesis Kit (Invitrogen), 
and the cDNA was then labeled with Cy-3, cleaned, quantified, and hybridized 
according to the manufacturer’s protocols (Roche - Nimblegen). Nimblegen full 
genome Mouse Expression arrays (12X135K) were washed and scanned at the Sabanci 
University Nanotechnology Research and Application Center-SUNUM. Results were 
processed using the ANAIS. Array quality was assessed at the probe level. Values for 3 
probes for each gene in each array were combined to summarize gene expression from 
probe sets. Robust Multi-Array Analysis back - ground normalization and quantile 
normalization were performed for intra- and inter-array normalization, respectively. 
Genes with signal intensities above a 95% random threshold were chosen for further 
studies. Differentially expressed genes were obtained based on the following criteria: 
fold-change >2 and p value < 0.05.  
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4. RESULTS 
 
 
 
 
4.1. PATZ1 is Expressed in Different Cell Lines 
 
 
 
In the present study, we identified the BTB-ZF family member PATZ1 transcription 
factor as a regulator of the tumor suppressor protein p53. PATZ1 regulates the 
transcriptional activity of p53 and has a marked impact on the DNA damage response 
induced by the treatment with the DNA damage inducing genotoxic drug doxorubicin 
(adriamycin). The human PATZ1 gene is located on the long arm (q12.2) of 
chromosome 22. The gene spans 20500 base pairs and consists of 6 exons (Ensemble 
accession number ENSG00000100105). There are 4 known alternatively spliced 
transcripts of PATZ1. All of the transcripts share the first two exons that encode most of 
the protein, including the BTB domain, the two AT hook motifs and the first 4 zinc 
finger motifs (Figure 4.1). The differences between the transcripts arise from the rest of 
the exons, which encode the C-terminus of the proteins. The human and the mouse 
PATZ1 genes share high homology, such that the identity of the protein products is over 
99%. We analyzed the expression of PATZ1 by exon specific amplification of 
alternatively spliced mRNAs and found that all  
37 
 
 
Figure 4.1: Exon structure of the human PATZ1 gene and the protein products encoded 
by alternative splice variants. The standard names of the alternative splice versions and 
the name and molecular size of the proteins they encode are indicated on the left. In the 
gene structure schematics, protein coding exons are shown in black boxes, introns are 
shown as lines with their size indicated in base pairs and 5’ and 3’ non-coding regions 
are shown as open boxes. In the protein schematics, grey boxes represent the protein-
protein interaction BTB/POZ domain, black boxes represent the DNA binding AT hook 
domains and numbered boxes represent the zinc finger motifs. Exon specific primers 
used for reverse transcription amplification are indicated as arrows above the exons. 
The exon structure of the mouse and human genes are highly similar, such that 
hPATZ1-001=mPATZ1-002, hPATZ1-002 (PATZ1Alt)=mPATZ1-012, hPATZ1-004 
(PATZ1)=mPATZ1-001 and hPATZ1-003=mPATZ1-003. 
 
four isoforms were expressed in various mouse T lymphocyte cell lines (Figure 4.2A), 
in the human colon carcinoma cell line HCT116 and its p53-/- version (Figure 4.2B). 
38 
 
We found that hPATZ1-004 and hPATZ1-002 are the major expressed isoforms in the 
cells examined in this study. For the sake of simplicity, throughout this thesis, we refer 
to these two isoforms as PATZ1 and PATZ1Alt, respectively.  
 
 
Figure 4.2: PATZ1 alternative splice variants are expressed in various cell lines. A. 
Expression of PATZ1 alternative splice variants in mouse T lymphocyte cell lines. 
Amplification with the primers indicated below the gels resulted in unique size 
amplicons indicating the presence of alternatively spliced mRNAs in the indicated cell 
lines. Gapdh specific primers were used to generate loading controls. B. PATZ1 
alternative splice variants are expressed in human HCT116 cells. Amplification with the 
primers indicated below the gels resulted in unique size amplicons indicating the 
presence of alternatively spliced mRNAs in HCT116 (left column) or HCT116 p53-/- 
(right column) cells. Semi-quantitative amplification was performed with 3 fold diluted 
cDNA samples used as amplification templates. GAPDH specific primers were used to 
generate loading controls. 
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4.2. Transcription Repression Activity of PATZ1 
 
 
 
PATZ1 was associated with transcription repression as well as transcription 
activation in various studies 113,114. We wanted to analyze and characterize the 
transcription repression activity of PATZ1. One known target of the PATZ1 protein is 
the CD4 T lymphocyte specific Thpok gene. This gene is repressed by PATZ1 and 
therefore not expressed in CD8 T lymphocytes 99. Previous experiments showed that 
when PATZ1 expression is deleted by knocking out the Patz1 gene in developing 
thymocytes of mice, the Thpok gene is activated in CD8+CD4- T-cells, where it 
normally stays repressed 99. In order to study the effects of overexpressing PATZ1 in 
CD8+CD4- cells, we used a model mouse where PATZ1 expression was specifically 
deleted in developing thymocytes. To obtain these mice, we bred a Patz1 gene targeted 
mouse which has a "floxed" Patz1 exon 1 flanked by loxP sequences (Patz1 f/f) with a 
transgenic mouse expressing the Cre recombinase specifically in developing T 
lymphocytes (Lck-Cre Tg) (Figure 4.3). Patz1 f/f x Lck-Cre Tg mice cannot express 
PATZ1 protein in their T lymphocyte populations. To study the effect of PATZ1 on 
Thpok gene expression, we bred these mice with knock in mice, where one allele of the 
Thpok gene was replaced with a GFP expression cassette, by which the Thpok 
expression can be assessed by GFP fluorescence in targeted lymphocytes. For this 
THPOK reporter experiment, we examined GFP expression in PATZ1 overexpressing 
(mCherry positive) CD8 T lymphocytes purified from lymph node T lymphocytes. 
 
We used this mouse model system to study the effect of PATZ1 re-expression on 
Thpok gene expression in Patz1 knockout CD8 SP T lymphocytes. To this end, we 
generated retroviruses expressing Patz1 cDNA along with an mCherry fluorescent 
reporter protein, and infected CD8 SP T lymphocytes from Patz1f/f x Lck-Cre Tg x 
Thpok::GFP mice (Figure D.1 and Figure 4.4). To generate PATZ1 and mCherry 
expressing retroviruses, we cloned the Patz1 cDNA into an mCherry expressing 
retroviral plasmid. In this system we track Patz1 expression in infected cells with 
mCherry fluorescence and endogenous Thpok gene expression using the  knock  in 
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Figure 4.3: Breeding of PATZ1 deficient or sufficient Thpok reporter mice. A. 
Generation of PATZ1 sufficient Thpok reporter mice. Exon 1 region of the Patz1 gene 
is flanked by two loxP sites. This mouse was bred with another knock in mouse, which 
introduced a GFP reporter into the Thpok gene locus. This mouse has a WT Thpok on 
one allele and the GFP reporter on the second allele. So we can use the GFP expression 
to study Thpok expression. B. PATZ1 deficient Thpok reporter mice. To delete the 
Patz1 gene, we crossed previous mouse with an Lck-Cre transgene mouse, which 
expresses cre, only in T lymphocytes. 
 
GFP fluorescence. In this system, Patz1 targeted CD8+CD4- T lymphocytes express 
GFP from the activated Thpok allele. When we re-establish PATZ1 expression in Patz1 
targeted CD8+CD4- T lymphocytes, we observed that THPOK expression was 
repressed (Figure 4.5). This experiment demonstrates that PATZ1 is a transcriptional 
repressor of the Thpok gene.  
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Figure 4.4: Retroviral infection of CD8 SP lymphocytes. We generated retroviruses 
expressing Patz1 cDNA or no cDNA (mock) along with an mCherry fluorescent 
reporter protein, and infected CD8 SP T lymphocytes from Patz1f/f x Lck-Cre 
Tg or Patz1f/f x Lck-Cre Tg x Thpok::GFP mice. Infected cells can be tracked 
by checking their mCherry expression by flow cytometry.  
 
To test the idea that the C-terminus of PATZ1 is required for the transcriptional 
repressor activity of PATZ1 on the Thpok gene expression, we used PATZ1Alt 
expressing retroviruses in our THPOK reporter experiment. We found that PATZ1Alt is 
capable of repressing Thpok gene expression to the same extent as PATZ1 (Figure 4.6). 
Therefore, we conclude that PATZ1 does not require its C-terminus for all transcription 
repressor activity. 
 
Next, we wanted to characterize the important residues of PATZ1 for transcriptional 
repressor activity. Using knowledge obtained by previous homology modeling studies 
and multiple protein sequence alignments of related BTB-ZF proteins (shown 
previously by Jitka Eryılmaz), we identified several candidate arginine residues within 
the zinc finger domain of PATZ1, which we thought would be critical for DNA 
recognition and binding. We mutated these arginine residues to glycine residues one by 
one (R372G, R403G, and R424G) in our Patz1 cDNA and mCherry expressing 
retroviral constructs. We used these constructs in the THPOK reporter experiment to 
assess if these PATZ1 mutants retained their transcription repressor activity (Figure 
4.7). We observed that among the mutants we tested, the arginine 372 (R372) and 
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Figure 4.5: Reconstruction of PATZ1 expression in PATZ1-/- CD8+CD4- cells re-
represses Thpok. We determined the effect of overexpressing PATZ1 on the expression 
of the Thpok gene (GFP) in the presence (PATZ1f/f, upper row) or in the absence 
(PATZ1f/f x LCK-CRE, lower row) of endogenous PATZ1 protein. Primary 
CD8+CD4- T lymphocytes were purified from thymus by flow cytometry, and infected 
with pMIG-mCherry based Patz1 cDNA expressing (right column) or empty retrovirus 
(left column). We assessed Thpok expression by GFP fluorescence and PATZ1 
expression by mCherry fluorescence. In this FACS plots, mCherry expression from the 
virus is shown on the X-axis and GFP expression from the endogenous Thpok gene 
locus is shown on the Y-axis. To see the inhibitory effects of PATZ1 expression on the 
Thpok expression, we should look at the decrease in the mcherry+/GFP+ (Q2 quadrant) 
in PATZ1 overexpressing and endogenous PATZ1 deficient cells (bottom right plot) 
compared to mock infected and endogenous PATZ1 deficient cells (bottom left plot). 
 
the arginine 424 (R424) residues are important for PATZ1 repressor activity because the 
R372G and the R424G mutants of PATZ1 cannot repress the expression of THPOK as 
efficiently as the WT PATZ1. These results indicate that PATZ1 binds to the ThPOK 
gene promoter using these residues and represses transcription. 
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Figure 4.6: PATZ1 does not require its C-terminus for its transcription repressor 
activity. We determined the effect of overexpressing PATZ1 or PATZ1Alt on the 
expression of the Thpok gene (GFP) in the presence (PATZ1f/f, upper row) or in the 
absence (PATZ1f/f x LCK-CRE, lower row) of endogenous PATZ1 proteins. Primary 
CD8+CD4- T lymphocytes were purified from thymus by flow cytometry and infected 
with pMIG-mCherry based Patz1Alt cDNA expressing (right column), Patz1 cDNA 
expressing (middle column) or empty retrovirus (left column). We assessed Thpok 
expression by GFP fluorescence and PATZ1 expression by mCherry fluorescence. 
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Figure 4.7: Several residues within the zing finger domain of PATZ1 are crucial for 
transcription repressor activity. We created site directed mutant PATZ1 constructs 
(R372G, R403G, and R424G) and determined the effect of overexpressing these on the 
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expression of the Thpok gene (GFP) in the absence (PATZ1f/f x LCK-CRE) of 
endogenous PATZ1 protein. Thymocytes were infected with pMIG-mCherry based WT 
or mutant PATZ1 expressing or empty retrovirus. mCherry vs. GFP profiles of 
CD8+CD4- thymocytes are on the left column and the GFP percentages within the 
mCherry positive sub-population is on the right column. Each row represents a 
construct used to infect the cells (mock, WT, or a mutant). We assessed Thpok 
expression by GFP fluorescence and PATZ1 expression by mCherry fluorescence. 
 
 
 
4.3. Global Effects of PATZ1 on Gene Transcription 
 
 
 
To gain new insights into the global effects of PATZ1 on transcription regulation, 
we performed genome scale RNA-Seq and microarray experiments. For these 
experiments, we used primary MEF cells that are an in vivo relevant and widely studied 
model system. We used MEFs, which were sufficient or deficient for PATZ1 (Figure 
4.8A). We isolated total RNA from these samples and analyzed the identity and quantity 
of transcribed genes by RNA sequencing performed on an Illumina HiSeq 2000 
platform at the Beijing Genomics Institute. We compared the expression values (RPKM 
- reads per kilobase per million) of genes in PATZ1 WT and KO MEFs (KO vs WT) 
and identified 156 differentially expressed genes (DEGs), of which 83 were upregulated 
and 73 were downregulated, in PATZ1 KO MEFs (Figure 4.8B). As PATZ1 is 
expressed in MEF, we concluded that these genes, which are up and downregulated, are 
direct targets which are respectively inhibited and activated by PATZ1. To obtain an 
overview of the biological processes that are significantly enriched in the DEGs in our 
KO vs. WT comparison, we performed DAVID 115 gene ontology (GO) analysis and 
found that in the absence of PATZ1, biological processes such as 1) cell adhesion, 2) 
neuron development and differentiation and 3) cell morphogenesis are significantly 
affected (Table 4.1). These processes that were significantly altered in the absence of 
PATZ1, correlate with and offer an explanation to several recent findings on the 
outcome of PATZ1 deficiency. Consistent with our GO term analysis, PATZ1-null mice 
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are born smaller in size and at a non-Mendelian frequency 101. Moreover these mice are 
born with defects in their central nervous systems 98 and furthermore mESC with 
impaired expression of PATZ1 lose their pluripotency and start to differentiate 100.  
 
GO Term Related to Biological Process 
 
P-Value 
 
GO:0007155~cell adhesion 7.65E-06 
GO:0022610~biological adhesion 7.82E-06 
GO:0043030~regulation of macrophage activation 1.26E-03 
GO:0007409~axonogenesis 1.81E-03 
GO:0048812~neuron projection morphogenesis 2.66E-03 
GO:0000902~cell morphogenesis 3.04E-03 
GO:0048667~cell morphogenesis involved in neuron differentiation 3.14E-03 
GO:0030182~neuron differentiation 4.22E-03 
GO:0048858~cell projection morphogenesis 5.23E-03 
GO:0032989~cellular component morphogenesis 6.50E-03 
GO:0000904~cell morphogenesis involved in differentiation 6.58E-03 
GO:0032990~cell part morphogenesis 6.58E-03 
GO:0031175~neuron projection development 7.51E-03 
GO:0018149~peptide cross-linking 7.73E-03 
GO:0048666~neuron development 8.26E-03 
GO:0030198~extracellular matrix organization 8.27E-03 
Table 4.1: Biological process GO terms that are enriched in our DEG set (generated by 
comparing KO vs. WT MEFs). P-values are calculated by DAVID and GO terms that 
have smaller than 0.01 P-values are listed. 
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Figure 4.8: Genome wide gene expression analysis of MEFs expressing or deficient 
in PATZ1 by RNA-Seq. A. PATZ1 knockout or WT MEFs were prepared from mouse 
embryo at E13.5. Total RNA was extracted, polyA selected and triplicate samples were 
sequenced at Beijing Genomics Institute on an Illumina HiSeq 2000 platform and 
analyzed using the R library DEseq. B. PATZ1 deficient MEFs (KO vs WT) 
differentially express 156 genes (83 upregulated and 73 downregulated), shown here by 
a heatmap. Fold change > 2, FDR < 0.001.  
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4.4. Effects of PATZ1 on Cell Proliferation 
 
 
 
4.4.1. PATZ1 Shortens Cellular Doubling Time  
 
 
Because PATZ1-null mice are born smaller in size 101 and because we identified 
biological process terms in PATZ1  deficient  MEFs  that  are  related  to  
developmental processes, we speculated that PATZ1 may have an effect on cellular 
 
Figure 4.9: MEFs lacking Patz1 expression proliferate slower. A. Confirmation of the 
genomic structure of Patz1 WT and Patz1 -/- MEFs. Primers specific for the size 
difference between the WT and targeted Patz1 alleles were used to amplify MEF 
genomic DNA. Amplicons showing the WT (+/+) or KO (-/-) status of these MEFs are 
indicated with arrows. B. Doubling time of Patz1 -/- and WT MEFs. Doubling time was 
calculated by xCELLigence RTCA DP system. C. Growth curves of Patz1 -/- (bold 
line) and WT (thin line) MEFs. Growth curves were calculated by the xCELLigence 
RTCA DP system using impedance measurements every 15 minutes. 
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proliferation rates. To this end, we examined the growth rates and doubling times of 
different cell lines. First, we generated MEFs from WT or PATZ1-/- C57BL/6 mice. 
We genotyped these MEFs to ensure that they really were WT or knock out for the 
PATZ gene (Figure 4.9A). We examined the growth properties of these MEFs in a real 
time cell analysis apparatus (Acea, California). PATZ1-/- MEFs proliferated 
significantly slower than WT MEFs and changes in proliferation rate were evident by 
calculated doubling time, which significantly increased for MEFs deficient for PATZ1 
expression (Figure 4.9B and 4.9C). Next, we created an overexpression  situation  to  
identify  the  effects  of excess PATZ1 on proliferation rates. We stably infected 
HCT116  cells  with  mock  or  Patz1  cDNA  encoding  viruses  (Figure E.1).   We 
 
 
Figure 4.10: PATZ1 overexpressing HCT116 cells proliferate faster. A. Generation of 
PATZ overexpressing HCT116 cells. Retroviruses were packaged and used to stably 
infect. Increased PATZ1 expression is shown in HCT116 cells infected with pBabe-
Puro based Patz1 cDNA expressing (P) but not empty virus (M) by anti-PATZ1 
blotting. B. Doubling time of mock or Patz1 infected HCT116. Doubling time was 
calculated by xCELLigence RTCA DP system. C. Growth curves of HCT116 cells 
infected with mock (thin line) or Patz1 (bold line) expressing retroviruses. Growth 
curves were calculated by the xCELLigence RTCA DP system using impedance 
measurements every 15 minutes. 
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Figure 4.11: PATZ1 expression is inversely correlated with doubling time in NIH3T3 
cells. A. Generation of PATZ overexpressing NIH3T3 cells. Western blotting with anti-
Patz1 antibodies demonstrates that PATZ1 expression is increased in NIH3T3 cells 
infected with pMIG-GFP/neo based retroviruses expressing either Patz1 cDNA (P) but 
not in empty virus infected cells (M). B. Generation of NIH3T3 cells with knocked 
down PATZ1 expression. Impaired PATZ1 expression is shown in NIH3T3 cells 
infected with LMP based shRNA against Patz1 (sh) but not empty virus (M) by anti-
PATZ1 blotting. C. Doubling time of mock or Patz1 infected NIH3T3 cells. Doubling 
time was calculated by xCELLigence RTCA DP system. D. Doubling time of mock or 
shRNA against PATZ1 infected NIH3T3 cells. 
 
confirmed the overexpression of PATZ1 protein levels by western blotting (Figure 
4.10A). In contrast to the knock-out situation in MEFs, overexpression of PATZ1 
protein in HCT116 cells increased the rate of proliferation and resulted in decreased 
doubling times (Figure 4.10B and 4.10C). In order to generalize the effects of PATZ1 
on cell proliferation, we alternatively knocked down the expression of endogenous 
PATZ1 using retroviruses expressing shRNAs or overexpressed PATZ1 ectopically in 
NIH3T3 cells (Figure F.1). We confirmed that cells stably infected with cDNA 
encoding retroviruses successfully overexpressed, while cells stably infected with 
shRNA encoding retroviruses knocked down PATZ1 expression (Figure 4.11A and 
51 
 
4.11B). Consistent with previous results with the MEF and HCT116 models, NIH3T3 
cells with enhanced PATZ1 expression displayed shorter doubling times, while PATZ1 
knockdown NIH3T3 displayed longer doubling times (Figure 4.11 and 4.11D). These 
data in 3 different cell types demonstrate that the PATZ1 protein has a positive impact 
on cellular proliferation rates. 
 
 
 
4.4.2. Effects of PATZ1 on Cell Cycle Progression 
 
 
We speculated that the positive effects of PATZ1 on cellular proliferation rates 
might be through the roles of PATZ1 on the regulation of cell cycle progression. In 
order to check this idea, we used the HeLa-Fucci model; an already established system 
in which progression of the cell cycle can easily be tracked by observing changes in the 
expression of fluorescent proteins during distinct phases of the cell cycle 116. This 
system relies on the cell cycle stage specific expression of the Geminin and Cdt1 
proteins, which are responsible for the licensing of replication origins, a precisely and 
strictly controlled process, which ensures that replication occurs only once during a cell 
cycle 117,118. The protein levels of Geminin and Cdt1 in cells are inversely regulated. 
Cdt1 levels are high during the G1 phase, but when cells enter S phase, Cdt1 protein 
rapidly gets degraded as Geminin starts to accumulate and stays stabilized during 
S/G2/M phases. Geminin expression ceases as the cells progress further into G1 phase 
again 117. The Fucci system takes advantage of this highly conserved mechanism by 
fusing a red fluorescent protein to Cdt1, and a green fluorescent protein to Geminin. 
Therefore, G1 cells are labelled red, cells that are in transition from G1 to S phase are 
labelled orange (i.e. both green and red), S/G2/M cells are labeled green, and cells that 
are in transition from M to G1 are colorless (i.e. neither green nor red) (Figure 4.12A 
and 4.12B). 
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Figure 4.12: The use of Fucci-expressing HeLa cells to investigate cell-cycle 
progression. A. Fucci-Hela cells express red or green fluorescent proteins depending on 
their cell cycle phases. Under the flourecent microscope, HeLa-Fucci cells display red 
or green fluorescence. B. Schematic representation of the colors of HeLa-Fucci cells 
during the cell cycle. G1 cells are red, cells that are in transition from G1 to S phase are 
orange, S/G2/M cells are green, and cells that are in transition from M to G1 are 
colorless C. Generation of PATZ1 overexpressing HeLa-Fucci cells. Retroviruses were 
packaged and used to stably infect HeLa-Fucci cells as described in methods section of 
this thesis. Increased PATZ1 expression is revealed by anti-PATZ1 blotting in HeLa-
Fucci cells infected with Patz1 cDNA expressing (P) but not empty (M) retrovirus. 
  
 We stably infected HeLa-Fucci cells with mock or Patz1 cDNA carrying 
viruses. The overexpression was confirmed by assessing protein levels using western 
blotting (Figure 4.12C). We analyzed these cells by flow cytometry in order to check 
their fluorescence patterns during the exponential growth phase (Figure 4.13). To our 
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surprise, cell cycle distribution among the mock or PATZ1 overexpressing Fucci-HeLa 
cells was not significantly different. Next, we wanted to check whether PATZ1 has any 
impact on cell cycle control during the DNA damage response. For this purpose, we 
induced DNA damage by treating PATZ1 overexpressing cells with the genotoxic drug 
cisplatin in order to arrest the cell cycle. Cisplatin was our cell cycle arrest drug of 
choice because the more commonly used doxorubicin is red fluorescent and interferes 
with the detection of Fucci fluorescence. 
 
 
Figure 4.13: Overexpression of PATZ1 in HeLa-Fucci cells does not alter cell-cycle 
distribution. HeLa-Fucci cells, which are infected either with mock or Patz1 cDNA 
carrying viruses, showing red (R+), orange (R+G+), and green (G+) fluorecence were 
analyzed with flow cytometry. 
 
 We found that cisplatin treatment caused G2 arrest (Figure 4.14) as HeLa-Fucci 
cells accumulate in the green fluorescence positive quadrant of the dot plot 
representation of the flow cytometric analysis. We followed the speed of the restoration 
of the cell cycle during the recovery of cells from cisplatin induced arrest. When we 
allowed arrested cells to recover for 24 hours, the cell cycle distribution was not 
different between the mock infected or PATZ1 overexpressing cells; however, there 
were minor differences when we prolonged the recovery period to 48 hours. The 
percentage of PATZ1 overexpressing cells returning to the G1 stage (red positive) was 
lower than cells infected with mock retrovirus. This result indicates that PATZ1 plays a 
role during cell cycle progression; however, the minor differences we observed suggest 
that PATZ1 is not a major player in this particular HeLa-Fucci system. We also wanted 
to check the effects of PATZ1 on cell cycle restoration without any induced DNA 
damage. For this purpose, we purified cells that are in the G1 (red) and S/G2/M (green) 
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phases from mixed cell populations using fluorescence-activated cell sorting (FACS) 
and observed the progression of the purified cells through their normal cell cycle 
(Figure 4.15). We did not detect any significant differences among the cell cycle 
restoration rates of mock infected or PATZ1 overexpressing HeLa- Fucci cells when 
they start the cell cycle from either the G1 or the S/G2/M phase. Thus, we concluded 
that PATZ1 did not significantly alter cell cycle distribution when overexpressed in 
HeLa-Fucci cells. However, xCELLigence experiments for the doubling time analysis 
had showed that PATZ1 expression shortens cellular doubling times. This inconsistency 
might be due to cell type specificity. To address this issue, we will study Fucci system 
in different cell types. 
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Figure 4.14: Cisplatin treatment results in a reversible G2 arrest in HeLa-Fucci cells. 
Mock infected HeLa-Fucci cells (left column) or PATZ1 overexpressing HeLa-Fucci 
cells (right column) were either untreated (first row) or treated with 0.5µM cisplatin for 
24 hours (second row). Cisplatin was withdrawn after 24 hours and the growth medium 
was refreshed to allow cells to recover for andditional 24 hours (third row) or 48 hours 
(last row). At every time point, the cell cycle stage of the cells was determined by flow 
cytometric analysis of fluorescence. 
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Figure 4.15:  Cells that are purified with respect to their cell cycle phase progress 
through the cell cycle and restore a normal distribution. Mock (upper left plot) or 
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PATZ1 overexpressing (upper right plot) HeLa-Fucci cells in the S/G2/M (green –left 
two columns) or G1 (red –right two columns) phases were purified using fluorescence-
activated cell sorting (FACS). Purified cells were allowed to restore their cell cycle 
distribution and analyzed by flow cytometry to check their cell cycle progression, at the 
indicated times (on the right side of the plots). 
 
 
 
4.5. PATZ1 Inhibits the Transcriptional Activity of p53 
 
 
 
p53 is a known regulator of the cell cycle and proliferative responses. In fact, p53 is 
the major player in these cellular responses, therefore any mechanism controlling the 
activity of p53 is of vital importance to cellular wellbeing and cancer research. This fact 
led us to investigate a possible direct link between PATZ1 and p53 proteins. Because 
PATZ1 can act as a transcription activator as well as a repressor, we hypothesized that 
PATZ1 might be a regulator of p53 activity. In order to study the effects of PATZ1 on 
the transcriptional activity of p53, we used different luciferase reporter constructs 
containing p53 response elements (RE); namely pG13, mG15, p21-LUC, and Puma-
LUC (Figure 4.16) 63,119. In the pG13 plasmid, the expression of the luciferase gene is 
controlled by 13 copies of canonical p53 REs. mG15 is a control plasmid for pG13, 
which contains 15 copies of mutated p53 REs. The p21-LUC plasmid contains the 
promoter of the CDKN1A gene, which contains a single p53 RE. The final plasmid, 
Puma-LUC contains the promoter of the PUMA gene and has 2 natural p53 REs. 
 
We first tested whether PATZ1 could affect the ability of p53 in activating 
transcription from the well established pG13 reporter in different cell lines. As 
expected, overexpressed p53 specifically activated transcription from this construct 
when co-transfected into HEK293T or HeLa cells (Figure 4.17A and 4.17B, 
respectively); however, it failed to induce luciferase expression from the mG15 reporter,  
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Figure 4.16: Schematic representation of the luciferase reporter constructs used in the 
study. There are 13 copies of canonical p53 response elements (RE) in the pG13 
plasmid driving the expression of the luciferase gene. mG15 is a control plasmid for 
pG13, in which there are 15 copies of mutated p53 REs. The promoter of the CDKN1A 
gene (with a single p53 RE) drives luciferase expression from the p21-LUC plasmid. 
The Puma-LUC plasmid carries the promoter of the PUMA gene and has 2 natural p53 
REs. 
 
showing that p53 activates REs selectively and specifically.  PATZ1 expression by itself 
did not activate transcription from pG13, while PATZ1 and p53 co-expression resulted 
in a significant decrease in p53 dependent transcription activity. Next, we repeated these 
luciferase assays with pG13, p21-LUC, and Puma-LUC reporter plasmids in a p53 
knock out background, using the HCT116 p53 -/- cell line, and found that PATZ1 could 
also inhibit the ability of p53 to activate transcription from these promoters (Figure 
4.18A, 4.18B, and 4.18C, respectively). In these experiments, the alternative splice 
variant PATZ1Alt could not suppress p53 activity as effectively  as  PATZ1.  
PATZ1Alt also does  not interfere with  PATZ1’s inhibitory role when co-expressed. 
Because the difference between PATZ1 and PATZ1Alt is in the C-terminus of the 
proteins, we concluded that the C-terminal region of PATZ1 is required for its 
inhibitory role on p53. Surprisingly, the PATZ1Alt protein could repress the Thpok 
gene indicating that the transcription inhibition by this transcription factor is context 
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Figure 4.17: PATZ inhibits p53 transcriptional activity in luciferase assays in various 
cell types.  Cells were transfected with different combinations of pG13 and mG15 
reporter constructs, and p53 and/or PATZ1 expression plasmids. p53 specifically 
activates the pG13 reporter (columns 1, 3), but not the pG15 reporter (columns 2, 4), 
while PATZ1 cannot activate pG13 or pG15 (columns 5, 6). PATZ can inhibit p53 
activity (columns 7). A. Transcriptional activity of p53 and PATZ1 transfected 
HEK293T cells. B. Transcriptional activity of p53 and PATZ1 transfected HeLa cells. 
 
dependent. Lastly, we assessed the domain requirements of p53 for the inhibition by 
PATZ1. We performed luciferase assays with WT p53 (p53α) or a naturally occurring 
alternative splice version (p53β) missing the C-terminal regulatory domain and 
observed that both p53α and p53β could activate transcription of the pG13 reporter 
construct. While PATZ1 co-expression could again dramatically inhibit p53α dependent 
transcription, the effect of PATZ1 on p53β dependent transcription was not as 
pronounced (Figure 4.18D). Thus, PATZ1 inhibits the transcriptional activity of p53 
and the inhibitory activity of PATZ1 on p53 requires the C-terminal domains of both 
proteins. 
 
 Next, we wanted to characterize the important residues of PATZ1 for its 
inhibitory roles on the transcriptional activity of p53. Using knowledge obtained by 
previous homology modeling studies (shown previously by Jitka Eryılmaz and Manolya 
Ün), we identified several critical residues that might be involved in PATZ1/DNA 
interaction and PATZ1/p53 interaction. We mutated these residues one by one (R372G,  
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Figure 4.18: PATZ1 inhibits p53 activity in luciferase assays with different luciferase 
constructs. A. HCT116 p53-/- cells were transfected with different combinations of 
pG13, p53, PATZ1 and PATZ1Alt expression plasmids. p53 specifically activates the 
pG13 reporter (columns 1, 2), while PATZ1 and PATZ1Alt cannot (columns 3, 4). 
PATZ1, but not PATZ1Alt can inhibit p53 activity (columns 5, 6). The same 
experiment was conducted with the p21-LUC reporter construct (B) and the Puma-LUC 
reporter construct (C). D. PATZ1 inhibits p53α better than the p53β alternative splice 
variant in luciferase assays. HEK293T cells transfected with different combinations of 
pG13, PATZ1 and p53α and p53β expression plasmids. p53α specifically activates the 
pG13 reporter (columns 1, 2), PATZ cannot activate pG13 (column 3) but can inhibit 
p53α activity (column 4).  p53β activates the pG13 reporter less efficiently compared to 
p53α (column 5) and PATZ fails to inhibit this activity efficiently (column 6). 
 
R394G, R403G, R424G, R456G, N495Y, D521Y, and a double mutant D521Y/D527Y) 
in our Patz1 cDNA expressing plasmids. We used these constructs in the luciferase 
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reporter assays to assess if these PATZ1 mutants retained their inhibitory roles on p53 
activity, using two different cell lines (Figure 4.19A and 4.19B). We observed that WT 
PATZ1 continued to repress p53 activity on the pG13 promoter and PATZ1Alt could 
not repress the activity to the same levels, as expected. R372G, R394G and R403G 
mutants lost almost all of the inhibitory roles on p53 activity. These residues are in the 
DNA binding domain of PATZ1 and this data suggests that PATZ1 might need to retain 
its DNA binding ability to inhibit p53 activity. Also the D521Y/D527Y mutant (double 
mutant) lost some of its inhibitory activity on p53. A co-worker, Nazli Keskin, had 
shown that this double mutant could not bind p53 while WT PATZ1 could. These data 
suggest that the D521 and D527 residues reside in the p53 binding domain of PATZ1 
and are important for the inhibitory roles of PATZ1 on p53 activity.  
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Figure 4.19 : Several residues in PATZ1 are crucial for inhibiting p53 activity. We 
created site directed mutant PATZ1 constructs at the indicated residues on the right side 
of the graph. Letters are abbreviations of amino acids. We determined the retained 
inhibitory roles of these mutants on p53 activity. A. HCT116 p53-/- cells were 
transfected with different combinations of pG13, p53, PATZ1, PATZ1Alt, and PATZ1 
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SDM expression plasmids. B. HEK293T cells were transfected with different 
combinations of pG13, p53, PATZ1, and PATZ1 SDM expression plasmids. 
 
 
 
4.6. PATZ1 in DNA Damage 
 
 
 
4.6.1. PATZ1 is Downregulated upon DNA Damage 
 
 
p53 is the major regulator of the DNA damage response. Because we found PATZ1 
as a regulator of the transcriptional activity of the p53 protein, we examined the role of 
PATZ1 in DNA damage as well. It is well known that the p53 protein is stabilized and 
accumulated in cells upon cellular stress such as DNA damage. We treated HCT116 
(Figure 4.20A) and U2OS (Figure 4.20C) human cancer cells with the DNA damage 
inducing genotoxic drug doxorubicin (adriamycin) in a time dependent manner and 
showed that p53 indeed accumulates in these cells. As a negative control, we used 
HCT116 p53-/- (Figure 4.20B) and H1299 (Figure 4.20D) cell lines, which lack a 
functional TP53 gene.  
 
The PATZ1 gene expresses 4 alternative splice variants that encode 74, 69, 58 and 
57 kDa proteins (Figure 4.21). The anti-PATZ1 antibody that we used in this study 
recognizes both human and mouse PATZ1 from an epitope located within the BTB 
domain of the proteins, therefore, it detects all 4 isoforms. However, this antibody could 
not differentiate between the mPATZ1-001 and -004 isoforms (corresponding to 
hPATZ1-004 and -001), and between the mPATZ1-012 and -003 isoforms 
(corresponding to hPATZ1-002 and -003) because of the similar molecular weights of 
these proteins.  
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Figure 4.20: p53 accumulates upon DNA damage induced by doxorubicin in various 
cell lines. Cells are treated for the indicated times with 1µM doxorubicin and whole cell 
lysates were immunoblotted with anti-p53 antibody. The presence of the absence of p53 
protein is indicated by arrows. A. HCT116, which express WT p53. B. HCT116 p53-/-, 
which is knocked out for p53. C. U2OS, which expresses WT p53. D. H1299, which is 
knocked out for p53. 
 
In order to identify the effects of DNA damage on the expression pattern of PATZ1, 
we treated mouse embryonic fibroblast (MEFs) with doxorubicin. We first confirmed 
the accumulation of p53 in these cells in response to DNA damage (Figure 4.22 lower 
panel) by demonstrating that p53 levels of untreated MEFs were indeed low and rapidly 
got induced upon treatment with doxorubicin. On the other hand, the amount of the 
different isoforms of PATZ1 protein were decreased after 16 hours of doxorubicin 
treatment and did not recover at later time points of the treatment (Figure 4.22 upper 
panel). We also used the human HCT116 cell line to generalize finding that PATZ1 is 
lost in response to DNA damage. We treated HCT116 cells with doxorubicin for 
different time periods and determined the levels of p53 and PATZ1 (Figure 4.23A). 
PATZ1 was also lost in HCT116 cells while p53 accumulated in response to 
doxorubicin treatment. Because PATZ1 loss correlated with p53 induction after 
doxorubicin treatment, we questioned if p53 induction was necessary for PATZ1 loss. 
To this end, we treated HCT116 p53-/- cells deficient in p53 expression with 
doxorubicin and found that PATZ1 was lost even in the absence of p53 (Figure 4.23A).  
65 
 
 
Figure 4.21: Schematic representation of proteins encoded by PATZ1 alternative splice 
variants. The standard names of human and mouse protein isoforms and molecular size 
of the proteins are indicated on the left. Grey boxes represent the protein-protein 
interaction BTB/POZ domain, black boxes represent the DNA binding AT hook 
domains and numbered boxes represent the zinc finger motifs. 
 
 
Figure 4.22: PATZ1 protein levels decrease upon doxorubicin treatment in MEFs. Cells 
were treated with 1µM doxorubicin for the indicated times and the whole cell lysates 
were immunoblotted with anti-PATZ1 (top row) or anti-p53 (bottom row) antibodies. 
The presence of PATZ1 isoforms and p53 are indicated by arrows. 
 
To determine whether PATZ1 loss was due to a reduction in protein levels or in mRNA 
transcript levels, we measured steady state PATZ1 mRNA levels by quantitative real-
time PCR, but could not detect significant changes in the time range where PATZ1 
protein levels dramatically decrease (Figure 4.23B). Thus, doxorubicin treatment likely 
results in the destabilization of PATZ1 protein isoforms and decreases cellular PATZ1 
levels. 
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Figure 4.23: PATZ1 protein levels, but not mRNA levels, decrease upon doxorubicin 
treatment of HCT116 cells, independent of the presence or absence of p53 protein. A. 
Cells were treated with 1µM doxorubicin for the indicated times and the whole cell 
lysates were immunoblotted with anti-PATZ1 (top row) or anti-p53 (middle row) 
antibodies. Equal loading was confirmed by immunoblotting the same membrane with 
anti-ACTIN antibody (bottom row). The presence of PATZ1 isoforms, p53, and ACTIN 
are indicated by arrows. B. Doxorubicin treatment does not alter mRNA levels of 
PATZ1. PATZ1 mRNAs were quantified by quantitative real-time PCR from HCT116 
(open circles) or HCT116 p53-/- (filled circles) cells, treated with 1µM doxorubicin for 
the indicated times. Expression was normalized to GAPDH expression. 
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4.6.2. Endogenous Transcriptional Activity of p53 
 
 
After testing the effects of PATZ1 on the transcriptional activity of p53 using 
artificial reporter constructs, we examined the changes in the expression of the known 
targets of the endogenous p53 protein upon DNA damage induction. The CDKN1A 
(p21/WAF) and PUMA genes are known to be dramatically induced by DNA damage in 
a p53 dependent way. Doxorubicin dramatically increased p21 and Puma gene 
expression in HCT116 cells with wild type p53, as assessed by quantitative real-time 
quantitative PCR (RT-qPCR) (Figure 4.24A and 4.24B, respectively). However, 
HCT116 cells stably expressing PATZ1 protein could not activate these two genes as 
effectively, especially after prolonged DNA damage. We conclude that PATZ1 is able 
to inhibit p53 dependent transcription activation. Next, we examined the effect of 
PATZ1 on the expression of known apoptosis related genes. To this end, we used a 
custom designed apoptosis panel developed by Roche (REF 05 532 850 001). These 
genes (BCL2, CASP9, CYCS, PARP1, AFM1, and POLG) are known to be differentially 
regulated by various apoptosis inducing signals. We used HCT116 cells infected with 
retroviruses either overexpressing PATZ1 or carrying no cDNA. We stressed these cells 
by doxorubicin to induce apoptosis (1µM for 8 h). We purified poly A tailed RNA and 
examined the expression of the apoptosis panel genes in these cells by RT-qPCR. 
Overexpression of PATZ1 did not have a significant effect on these apoptosis related 
genes (Figure 4.25). Although we did not observe a significant difference in the 
expression of these genes, as seen in section 4.6.3, global analysis of gene expression in 
response to DNA damage may reveal the function of PATZ1 on other apoptosis or cell 
cycle related genes. 
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Figure 4.24: PATZ1 impairs the up-regulation of p53 dependent genes in doxorubicin 
treated cells. RT-PCR analysis reveals PATZ1 overexpressing HCT116 cells (filled 
circles solid line) express less p21(A) and Puma (B) mRNA compared to mock infected 
cells (open circles thin line) upon 1µM doxorubicin treatment. mRNA levels were 
assessed by RT-qPCR using PCR primers to amplify the mRNAs specified on top of the 
graphs. Expression is normalized to GAPDH expression. 
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Figure 4.25: Overexpression of PATZ1 did not have a significant effect on apoptosis 
related genes. RT-PCR analysis reveals PATZ1 overexpressing HCT116 cells did not 
significantly changed several apoptosis related genes in response to 1µM 8 h treatment 
of doxorubicin. mRNA levels were assessed by RT-qPCR using PCR primers to 
amplify the mRNAs specified on top of the graphs. Expression is normalized to 
RN18S1 expression.  
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4.6.3. Global Effects of PATZ1 on Gene Transcription in Response to DNA 
Damage 
 
 
In section 4.6.2, we tested the effects of PATZ1 on only two p53 targets that are 
major regulators of the p53 dependent DNA damage response. On the other hand, we 
also showed the global effects of PATZ1 on gene transcription independent of DNA 
damage. Here, we used the DNA damage inducing drug doxorubicin on MEF cells and 
performed RNA-seq analysis in these samples, similar to the experiments in section 4.3 
(Figure 4.26A). We compared the gene expression patterns of PATZ1 WT MEFs 
(WTdox vs. WT) or KO MEFs (KOdox vs. KO) either treated with doxorubicin or 
untreated (Figure 4.26B, left panel). After doxorubicin treatment, there was a substantial 
number of DEGs that were either upregulated or downregulated in both groups. GO 
term analysis revealed that DEGs in both comparisons were enriched for established 
p53 gene targets and responses, such as cell cycle, apoptosis, growth and proliferation 
(Table 4.2 and Figure 4.27); confirming that doxorubicin induces p53 responses in our 
system in the presence or absence of PATZ1. To assess the effect of PATZ1 on these 
p53 responses, we analyzed the relevance of the DEGs found in the absence of PATZ1 
after doxorubicin treatment (i.e. the DEGs that are found only in KOdox vs. KO but not 
in WTdox vs. WT, plus the DEGs that are changed by 2-fold or more in KOdox vs. KO 
compared to their counterparts in WTdox vs. WT samples). We divided this DEG set 
into up- and down-regulated DEG subsets. We performed functional annotation analysis 
for these two new sets and noticed that genes upregulated in the absence of PATZ1 
(Table 4.3) were enriched in biological processes such as DNA packaging, chromatin 
assembly, and nucleosome assembly, which may be related to heterochromatin 
formation. Conversely we found that genes downregulated in the absence of PATZ1 
(Table 4.4) were enriched in processes such as positive regulation of transcription, 
positive regulation of macromolecule biosynthetic processes, and regulation of RNA 
metabolic processes, which may be related to gene suppression. These results suggest 
that PATZ1 might be a chromatin remodeling factor either by itself or maybe through 
its interactions with co-factors.  
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Figure 4.26: Genome wide gene expression analysis of MEFs expressing or deficient in 
PATZ1 upon DNA damage induction, by RNA-Seq. A. PATZ1 knockout or WT MEFs 
were prepared from mouse embryo at E13.5. Early passage MEFs were either untreated 
or treated with 1uM doxorubicin for 8 hours. Total RNA was extracted, polyA selected 
and triplicate samples were sequenced at Beijing Genomics Institute on an Illumina 
HiSeq 2000 platform and analyzed using the R library DEseq. B. Comparison of our 
RNASeq analysis with previous experiments. Left panel shows the up (red) and down 
(blue) regulated genes in our experiment. Right panel shows the same data filtered on 
p53 regulated genes from previously published data. 721 p53 regulated-genes 
(536+185) continue to be differentially expressed in response to doxorubicin, 
independent of the presence or absence of PATZ1. 71 p53 target genes (48+23) failed to 
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be differentially expressed in PATZ1 KO MEFs and 24 genes (14+10) were uniquely 
controlled in PATZ1 KO MEFs. Fold change > 2, FDR < 0.001. 
 
GO Term Related to  
Biological Process 
 
P-Value in  
Wtdox vs WT 
 
P-Value in  
Kodox vs KO 
 
GO:0007049~cell cycle 6.69E-04 4.25E-03 
GO:0010941~regulation of cell death 3.89E-04 1.16E-03 
GO:0040008~regulation of growth 4.21E-03 1.76E-03 
GO:0042127~regulation of cell proliferation 2.13E-09 6.05E-10 
GO:0042981~regulation of apoptosis 1.08E-03 2.98E-03 
Table 4.2: Biological process GO terms that are enriched in our DEG set fromRNA-Seq 
(generated by comparing WTdox vs. WT and KOdox vs. KO MEFs). P-values are 
calculated by DAVID and GO terms that have smaller than 0.01 P-values are listed. 
 
To further analyze differentially expressed genes in the presence or absence of 
PATZ1, with or without doxorubicin treatment, we analyzed RNA isolated from various 
MEF cells with Nimblegene microarrays. To analyze the effects of longer term DNA 
damage, distinct from the RNAseq experiments, we treated our MEF samples with 
doxorubicin for 24 hours. The suppression of gene expression was more evident in the 
results of this microarray such that the number of uniquely downregulated genes in 
KOdox vs. KO samples increased compared to uniquely upregulated genes (Figure 
4.28). As it was the case in RNA-Seq results, in the microarray results, GO terms were 
also enriched for transcription regulation in the downregulated gene set (uniquely in 
KOdox vs. KO) (Table 4.5). However, to our surprise, upregulated genes (uniquely in 
KOdox vs. KO) did not exhibit enriched GO terms related to chromatin remodeling in 
our microarray results, as it was the case for the upregulated gene set in RNA-Seq 
(Table 4.6). Thus, we conclude that PATZ1 might be activating gene transcription in 
response to DNA damage.  
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Figure 4.27: Doxorubicin treatment changes the expression of p53 target genes. Gene 
set enrichment analysis (GSEA) of p53 regulated genes from previously published 
data120 in our DEG sets in WTdox vs. WT and KOdox vs. KO comparisons. 
 
In order to identify the effects of PATZ1 specifically on p53 target genes, we 
filtered our RNA-Seq data using data from a previously published RNA-Seq 
experiment, which defines p53 target genes in MEFs also treated with doxorubicin as a 
DNA damage inducer 120 (Figure 4.26B, right panel). In this previously published 
experiment, WT and p53 deficient MEFs were compared to identify direct 
transcriptional targets of p53 upon short time doxorubicin treatment. This study 
identifies 918 p53 target genes that are upregulated and 405 genes that are 
downregulated. Among these genes, we identified 721 genes that continue to be 
differentially expressed in response to doxorubicin, independent of the presence or 
absence of PATZ1, 71 genes failed to be differentially expressed in PATZ1 KO MEFs 
and 24 genes were uniquely controlled in PATZ1 KO MEFs. When we looked at the 
genes that are immediate targets of p53 (Kyoto Encyclopedia of Genes and Genomes - 
KEGG mouse p53 pathway - mmu04115), we identified genes that are differently 
affected upon doxorubicin treatment in PATZ1 deficient MEFs compared to WT MEFs 
(Figure 4.29). We also looked at the genes, whose expression was uniquely changed 
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either in PATZ1 KO or in WT MEFs upon doxorubicin treatment. We present these 
findings in a Cytoscape image, which demonstrates that PATZ1 deficiency affected the 
expression of several p53 target genes (Figure 4.30). Therefore, we conclude that the 
absence of PATZ1 results in an alteration of the expression of p53 target genes. The 
microarray and RNA-Seq data presented in this study will be deposited in NCBI’s Gene 
Expression Omnibus (GEO) 121.  
 
GO Term Related to Biological Process 
 
P-Value 
 
GO:0007423~sensory organ development 6.35E-05 
GO:0007389~pattern specification process 6.26E-04 
GO:0006334~nucleosome assembly 1.97E-03 
GO:0031497~chromatin assembly 2.26E-03 
GO:0065004~protein-DNA complex assembly 2.42E-03 
GO:0034728~nucleosome organization 2.42E-03 
GO:0040007~growth 2.57E-03 
GO:0043583~ear development 2.68E-03 
GO:0007167~enzyme linked receptor protein signaling pathway 3.93E-03 
GO:0048839~inner ear development 5.01E-03 
GO:0045165~cell fate commitment 5.06E-03 
GO:0006814~sodium ion transport 7.34E-03 
GO:0070374~positive regulation of ERK1 and ERK2 cascade 8.37E-03 
GO:0006323~DNA packaging 9.68E-03 
GO:0048663~neuron fate commitment 9.89E-03 
Table 4.3: Biological process GO terms that are enriched in our DEG set from RNA-
Seq that consists of upregulated genes uniquely in KOdox vs. KO and of more 
upregulated genes in KOdox vs. KO compared to WTdox vs. WT. P-values are 
calculated by DAVID and GO terms that have smaller than 0.01 P-values are listed. 
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Geno Ontology Term Related to Biological Processes 
 
P-Value 
 
GO:0051252~regulation of RNA metabolic process 1.33E-07 
GO:0006355~regulation of transcription, DNA-dependent 5.10E-07 
GO:0045449~regulation of transcription 1.87E-06 
GO:0006350~transcription 1.01E-04 
GO:0006357~regulation of transcription from RNA polymerase II promoter 2.47E-04 
GO:0045935~positive regulation of nucleic acid metabolic process 3.40E-04 
GO:0010604~positive regulation of macromolecule metabolic process 3.63E-04 
GO:0051173~positive regulation of nitrogen compound metabolic process 5.03E-04 
GO:0010628~positive regulation of gene expression 5.23E-04 
GO:0010557~positive regulation of macromolecule biosynthetic process 5.53E-04 
GO:0031328~positive regulation of cellular biosynthetic process 9.16E-04 
GO:0045941~positive regulation of transcription 9.98E-04 
GO:0009891~positive regulation of biosynthetic process 1.02E-03 
GO:0016071~mRNA metabolic process 4.71E-03 
GO:0006402~mRNA catabolic process 5.08E-03 
GO:0006401~RNA catabolic process 8.18E-03 
GO:0045893~positive regulation of transcription, DNA-dependent 9.82E-03 
Table 4.4: Biological process GO terms that are enriched in our DEG set from RNA-
Seq that consists of downregulated genes uniquely in KOdox vs. KO and of more 
downregulated genes in KOdox vs. KO compared to WTdox vs. WT comparison. P-
values are calculated by DAVID and GO terms that have smaller than 0.01 P-values are 
listed. 
 
 
Figure 4.28: Genome wide gene expression analysis of MEFs expressing or deficient in 
PATZ1 by microarray. PATZ1 knockout or WT MEFs were prepared from mouse 
embryo at E13.5. Early passage MEFs were either untreated or treated with 1uM 
doxorubicin for 24 hours. Total RNA was extracted, polyA selected, converted to 
dsDNA and triplicate samples were hybridized on Nimblegen full genome mouse 
expression array. Panel shows the up (red) and down (blue) regulated genes. Fold 
change > 2, FDR < 0.05. 
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Geno Ontology Term Related to Biological Processes 
 
P-Value 
 
GO:0048477~oogenesis 0.001637235 
GO:0007292~female gamete generation 0.006154979 
GO:0000904~cell morphogenesis involved in differentiation 0.006844041 
GO:0042035~regulation of cytokine biosynthetic process 0.009823388 
Table 4.5: Biological process GO terms that are enriched in our DEG set from 
microarray that consists of upregulated genes uniquely in KOdox vs. KO. P-values are 
calculated by DAVID and GO terms that have smaller than 0.01 P-values are listed. 
 
Geno Ontology Term Related to Biological Processes 
 
P-Value 
 
GO:0045449~regulation of transcription 4.66E-04 
GO:0006399~tRNA metabolic process 4.82E-05 
GO:0006396~RNA processing 3.38E-03 
GO:0045927~positive regulation of growth 3.67E-03 
GO:0008637~apoptotic mitochondrial changes 4.06E-03 
GO:0007005~mitochondrion organization 4.40E-03 
GO:0007006~mitochondrial membrane organization 4.70E-03 
Table 4.6: Biological process GO terms that are enriched in our DEG set from 
microarray that consists of downregulated genes uniquely in KOdox vs. KO. P-values 
are calculated by DAVID and GO terms that have smaller than 0.01 P-values are listed. 
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Figure 4.29: P53 pathway is affected in doxorubicin treated PATZ1 deficient MEFs. 
p53 pathway from KEGG (mmu04115) was visualized in Cytoscape for WTdox vs. WT 
and KOdox vs. KO comparisons. Genes with gray nodes have no significant differential 
read data. Down-regulated and up-regulated genes were visualized with blue and red 
respectively 
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Figure 4.30: Doxorubicin treatment in the absence of PATZ1 results in an alteration of 
the expression of p53 target genes. We found that 71 p53 target genes (48+23) failed to 
be differentially expressed in PATZ1 KO MEFs and 24 genes (14+10) were uniquely 
controlled in PATZ1 KO MEFs. Cytoscape analysis shows that PATZ1 knock out 
MEFs treated with doxorubicin failed to control these p53-dependent genes.  
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4.7. Preliminary Results for Future Directions 
 
 
 
4.7.1. Knocking out PATZ1 in Human Cell Lines 
 
 
Being able to study the functions of PATZ1 in a PATZ1 null cell line system would 
offer numerous advantages. For this reason, we wanted to knockout the human PATZ1 
gene using  TALEN  (Transcription Activator-Like  Effector  Nuclease) genome editing 
tools. TALENs are a novel method for genome engineering, in which a genomic locus 
of interest can be specifically and efficiently targeted to be modified using custom 
 
 
Figure 4.31: TALENs against PATZ1 genomic locus. TALENs cut PATZ1 gene near 
the translation initiation start site in the first exon. 
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Figure 4.32: A closer look to TALENs on PATZ1 genomic sequence. fwdTALEN and 
revTALEN will bind to the DNA from just a few bases downstream of the translation 
initiation site of PATZ1. A BglI restriction enzyme recognition site is located in 
between the TALEN pair. Specific primers shown by light green-colored arrows are 
used to amplify the genomic region encompassing the site of indels. 
 
designed proteins 122. TALENs are sequence specific nucleases, which create DNA 
double strand breaks (DBS) at the targeted genomic loci. Cells with DSB activate their 
intrinsic non-homologous end-joining (NHEJ) mechanism to repair the breaks. During 
this inefficient repair process, insertions of new nucleotides or deletions of some 
existing nucleotides (INDELs) result in the mutation of the targeted locus. If the 
targeted sequence is in a protein coding exon of a gene, INDEL mutation disturbs the 
gene structure and the mRNA reading frame leading to a gene knock-out situation 123. 
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Figure 4.33: RFLP analysis to the single-cell-derived-colonies of HCT16 cells after 
TALEN transfection. Genomic DNA was isolated from the colonies and the PCR 
products amplified from the site of TALEN recognition were subjected to RFLP 
analysis with BglI enzyme. First column of each colony (col) is uncut control (no 
enzyme), second column is BglI digestion.  
 
We designed TALENs against a sequence near the translation start site of the 
PATZ1 gene (Figure 4.31). We predicted that TALEN induced NHEJ would disrupt the 
PATZ1 gene reading frame resulting in out-of-frame transcripts with premature stop 
codons, thus creating a Patz1-/- genotype. We designed these TALENs so that a BglI 
restriction enzyme site within the TALEN target sequence would allow the screening of 
mutated PATZ1 sequences by RFLP (restriction fragment length polymorphism). Our 
strategy would allow us to identify cells with mutations in the PATZ1 gene because 
TALEN mediated mutations in the targeted exon would disrupt the BglI site revealed in 
an RFLP assay (Figure 4.32). We generated PATZ1 gene targeting TALEN proteins 
using the Golden Gate cloning procedure122. We transfected TALEN expression 
constructs to HCT116 cells, and generated single cell derived colonies. We isolated 
genomic DNA from these colonies and amplified the target region in a PCR reaction. 
We digested amplicons from each colony with BglI to assess the mutation rate. To date, 
we screened some colonies using this RFLP assay; however, we could not successfully 
identify a mutated colony, in which the PATZ1 locus is mutated (Figure 4.33). We are 
in the process of screening more colonies and optimizing different factors that will 
improve the efficiency of TALEN mediated genomic mutation.  
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4.7.2. Impact of PATZ1 Expression on Tumorigenesis in Murine Xenograph 
Models 
 
 
In this study, we tried to understand the molecular mechanisms that PATZ1 
controls, using in vitro techniques. To correlate these in vitro findings with in vivo 
potential impacts of PATZ1 in tumorigenesis, we planned xenograph experiments in 
mice. In order to study PATZ1 in tumorigenesis, we created EL4-Ova mouse cell lines 
that overexpress or knock-down PATZ1. This cell line is known to develop solid tumors 
once subcutaneously injected into immunocompromised nude mice 124. We confirmed 
that the cells are expressing higher or lower levels of PATZ1 in the overexpression or 
knocked-down conditions, respectively (Figure 4.34A and 4.34B). These newly created 
cells will be used for xenotransplantation into nude mice through subcutaneous 
injection. We will assess the impact of PATZ1 on tumor development by measuring the 
sizes of the tumors that rise from injected EL4-Ova cells.  
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Figure 4.34: Creating stably PATZ1 overexpressing or knocked-down EL4-Ova cells. 
A. EL4-Ova cells were infected with mock shRNA carrying (in LMP backbone) virus, 
or two different shRNAs against PATZ1 (sh29 and sh62 in LMP backbone). Since LMP 
plasmid has GFP marker, we checked the infection efficiency by looking at the GFP 
fluorescence levels of the cells using flow cytometry B. Generation of PATZ 
overexpressing or knocked-down EL4-Ova cells. Retroviruses were packaged and used 
to stably infect. On the left panel, increased PATZ1 or PATZ1Alt expression is shown 
in EL4-Ova cells with pBabe-Puro based Patz1 or Patz1Alt cDNA expressing but not 
mock virus by anti-PATZ1 blotting. On the right panel, anti-PATZ1 for knocked-down 
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EL4-Ova cells described in A. was shown. Equal loading was confirmed by 
immunoblotting the same membrane with anti-ACTIN antibody, on the lower panel. 
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5. DISCUSSION  
 
 
 
 
Our current study identifies the BTB-ZF transcription factor PATZ1 as a regulator 
of the DNA damage response by modulating the activity of the p53 tumor suppressor 
protein in this pathway. We found that PATZ1 is sensitive to DNA damage because the 
cellular protein level of PATZ1 decreases upon DNA damage induction. The role of p53 
in the DNA damage response is extensively studied in the literature and it is well 
established that p53 protein gets stabilized and rapidly accumulates in cells in response 
to a wide variety of cellular stress, including DNA damage. The consequent loss of 
PATZ1 as p53 increases led us to investigate the role of PATZ1 in the DNA damage 
response pathway and on the function of p53 within this pathway. We found that 
PATZ1 indeed plays a role in DNA damage pathway by modulating the transcriptional 
activity of p53.  
 
PATZ1 belongs to the BTB-ZF family, a class of transcription factors that have a 
BTB domain for protein-protein interactions and a ZF domain for protein-DNA 
interactions. These kinds of transcription factors are generally versatile in modulating 
transcription. They can directly activate or repress gene transcription by binding to the 
promoter of the target genes or they can indirectly change the transcription of a gene by 
modulating the activity of other transcription factors by interacting with them 125,126. 
The BTB domain is capable of homo- or hetero-dimerization with other BTB-domain 
containing transcription factors and with co-factors, like HAT and HDAC 78,79. 
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Moreover, these transcription factors can act as chromatin remodeling factors depending 
on their interaction partners. BTB-ZF proteins play important roles in tumorigenesis, 
especially in cases of genetic abnormalities like translocations, they are also responsible 
for aberrant epigenetic modifications and chromatin remodeling, therefore they may 
contribute to the undesirable alteration of gene expression that may favor tumorigenesis 
80,83,88,127. PATZ1 is found to be upregulated in different cancers and its downregulation 
is associated with increased apoptosis 97,106,107. Like many other BTB-ZF family 
members, the translocation of the PATZ1 gene is also a cancer inducing event, more 
specifically Ewing’s sarcoma104. PATZ1 has important roles during embryogenesis 
because in the absence of PATZ1, mice are born smaller in size, infertile, very prone to 
spontaneous lymphoma occurrence, and have impaired central nervous system 
development 98,101. PATZ1 is required for the maintaining of the pluripotency of mESC 
and contributes to embryonic development 100. These findings place PATZ1 as an 
important candidate in tumorigenesis. 
 
PATZ1 was originally identified to be expressed in brain, thymus, fetal liver, and 
bone marrow, and especially in B-cell lines in different stages of development 92. We 
documented its expression in various cell types, both from primary cells and cancer cell 
lines. We found that it is expressed in primary MEFs and mouse thymocytes, different 
mouse T lymphoma cell lines, human colon carcinoma HCT116 cell lines, human 
epithelial carcinoma HeLa cell line and mouse fibroblast NIH3T3 cell lines (Figures 
4.2A, 4.2B, 4.10A, 4.11A, 4.12C, 4.22). The protein sequence of PATZ1 is highly 
conserved among mammalian orthologues, suggesting an important and ancient role. 
The gene structure is almost the same between mouse and human genomes and there is 
over 99% homology between the protein sequences (Figure 4.1). There are 4 alternative 
splice variants of PATZ1 (Figure 4.21). In our study, the antibody that we used for 
PATZ1 detection was against the BTB domain of the protein, which is included in all of 
the variants. Therefore, we could not differentiate between the longer two variants 
(which have very similar molecular weights, i.e. 69 and 74 kDa) and the shorter two 
variants (58 and 59 kDa) in western blotting.  
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In different studies, PATZ1 repressed or activated gene transcription, depending on 
the cellular context and the target gene 93,94. We analyzed and characterized the 
transcriptional repression activity of PATZ1. PATZ1 was found to be controlling the 
expression of the Thpok gene because in the absence of PATZ1, the endogenous Thpok 
gene was derepressed in CD8+CD4- thymocytes, in which it normally stays repressed. 
We restored PATZ1 expression in these PATZ1 null cells and showed that PATZ1 re-
represses Thpok, indicating that PATZ1 normally suppresses Thpok (Figure 4.5). 
Structure function studies in Thpok reporter experiments revealed important residues 
within the zinc finger domain of PATZ1. These residues are conserved among several 
BTB-ZF proteins and are important for contacting DNA (shown previously by Jitka 
Eryilmaz). This explains their importance in the transcriptional repression activity of 
PATZ1 because PATZ1 may interact with DNA through these residues. Because we 
defined the role of PATZ1 on Thpok gene expression, we plan to clone this promoter 
into a luciferase reporter construct in order to use it for further structure function 
analyses. 
 
Aberrant overexpression of PATZ1 was found in various cancers and its 
overexpression rescued old and senescent fibroblasts 102,106,107. These data indicates that 
PATZ1 overexpression might favor uncontrolled cell growth. Particularly, we 
hypothesized that PATZ1 might play role in cellular proliferation, a process, which is 
strictly regulated by p53. We found that PATZ1 deficiency results in increased doubling 
time, indicating that these cells grow slower compared to their WT partners, whereas 
PATZ1 sufficiency or overexpression leads to decreased doubling time, meaning faster 
growth, in various cell types that we tested (Figure 4.9B, 4.10B, 4.11C, and 4.11D). 
These findings suggest that PATZ1 positively controls cell growth; however, whether 
this role of PATZ1 is p53-dependent remains unknown. The strength of these results 
comes from the real time analysis of cell growth using xCELLigence RTCA DP 
technology. In our doubling time calculation experiments, we did not use end point 
assays, in which cells are harvested and counted at several time points; instead we 
analyzed the cell growth in real time, in as short as 15 minutes intervals for over 100 
hours. This technical advantage allowed us to draw a more definitive and reliable 
conclusion. We checked if this proliferative role of PATZ1 is through cell cycle control. 
To this end, we utilized HeLa-Fucci cells, in which progression of the cell cycle can 
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easily be tracked by observing changes in the expression of fluorescent proteins during 
distinct phases of the cell cycle 116. However, we did not detect any cell cycle 
distribution difference between mock and PATZ1 overexpressing HeLa-Fucci cells 
(Figure 4.13). In fact, HeLa cells are human papilloma virus (HPV)-transformed cells, 
which express high levels of the HPV E6 protein 128. Although, HeLa cells express WT 
p53, E6 increases the turnover of p53 protein by interacting with it; therefore the effects 
of E6 on p53 are analogous to an inactivating mutation of p53. In our HeLa-Fucci 
system, the p53 pathway might be inactivated and this might be the reason why we did 
not observe any effects of PATZ1 on cell cycle distribution. The HeLa-Fucci system 
might not be the ideal model to study the role of p53 dependent cell cycle alterations. 
We plan to repeat these cell cycle control experiments in p53 WT cells with functional 
p53. 
 
We identified a direct link between p53 and PATZ1 using luciferase reporter assays 
and quantitative measurements of mRNA levels of p53 target genes. We found that p53 
activates transcription from different luciferase constructs, which contain p53 response 
elements (REs), and that PATZ1 inhibits the transcriptional activity of p53 on these 
reporters (Figure 4.17A, 4.17B, 4.18A, 4.18B, 4.18C 4.18D, 4.19A, and 4.19B). We 
also found that the C-terminal zinc finger domain lacking alternative splice variant of 
PATZ1, PATZ1Alt, could not suppress p53 activity as effectively as PATZ1 (Figure 
4.18A, 4.18B, and 4.18C). On the other hand, PATZ1 could not repress the 
transcriptional activity of the C-terminal lacking alternative splice variant of p53, p53β, 
as effectively as it inhibits p53 (Figure 18D). Indeed, in order to inhibit the 
transcriptional activity of p53, PATZ1 physically interacts with p53 and this interaction 
is through the C-terminal domains of both proteins (shown by Nazli Keskin). Therefore, 
we conclude that PATZ1 inhibits the transcriptional activity of p53 by binding the C-
terminal regulatory region of p53 using its own C-terminal zinc finger domain. In facts, 
there are other BTB-ZF family members that bind p53 using their zing finger domains 
and that inhibit the DNA binding activity of p53 either by displacing p53 from its DNA 
targets or by competing in binding to the p53 REs 125,126. Indeed, Nazli Keskin also 
found that PATZ1 utilizes these two mechanisms to inhibit the DNA binding of p53. 
We also observed the inhibitory effects of PATZ1 on the transcriptional activity of p53 
in endogenous p53 target genes. Upon DNA damage, p53 could not induce the 
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expressions of known p53 targets, namely p21 and PUMA, as effectively in the 
presence of enforced overexpression of PATZ1 (Figure 4.24A and 4.24B). We plan to 
perform in vitro binding assays between PATZ1 and p53 that are expressed and purified 
from bacteria, so that we will be able to map the physical interaction between these two 
proteins and to define the domain requirements for this interaction.   
 
DNA damage leads to p53 stabilization and accumulation, a marked initiator event for 
the downstream processes taking place in DNA damage response. We detected PATZ1 
protein loss in DNA damage induced cells and generalized this phenomenon using two 
different cell types (Figure 4.22 and 4.23A). Because PATZ1 loss correlated with p53 
accumulation after doxorubicin treatment, we questioned if p53 accumulation was 
necessary for PATZ1 loss. To this end, we treated HCT116 cells lacking p53 with 
doxorubicin and found that PATZ1 loss was still evident even in the absence of p53. 
However, it is noteworthy that PATZ1 loss progressed faster in the absence of p53, 
suggesting that p53 might be protecting PATZ1 from degradation. In order to generalize 
this idea, we created MEFs lacking p53 expression and we will test these cells for the 
rate of PATZ1 loss upon doxorubicin treatment by comparing them to their WT 
counterparts. It would also be interesting to see the p53 accumulation rates in PATZ1 
null cells upon DNA damage induction and for this we plan to use PATZ1 -/- and WT 
MEFs in future experiments. The steady state levels of PATZ1 mRNA did not change 
upon doxorubicin during the time periods that we observed PATZ1 protein loss (Figure 
4.23B). This indicates that the loss is in protein levels and is regulated by protein 
degradation and not at the transcription level. There might be post-translational 
modifications on PATZ1 protein that control the stability of the protein, like 
ubiquitination or phosphorylation. To date, a post- translational modification of the 
PATZ1protein has not been reported. Identification of such post-translational 
modifications would give insights into PATZ1 function.  
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Figure 5.1: Our model of PATZ1 depicting its roles in the absence or presence of 
DNA damage. A. PATZ1 is capable of both repressing (depicted as tight DNA 
structure) and activating (depicted as relaxed DNA structure) the gene transcription. B. 
PATZ1 continues to its transcription activation and repression activities in the presence 
of DNA damage; however, it rather activates the gene transcription than repressing it. 
C. PATZ1 also affects the target specificity of p53 in the presence of DNA damage.   
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We listed the direct target genes of PATZ1 and the global effects of PATZ1 on p53 
target genes by performing genome scale RNA-Seq and microarray experiments. In 
contrast to the several findings that PATZ1 functions as more of a transcription 
repressor, we found that PATZ1 possesses both transcription activation and repression 
activities (Figure 4.8A, 4.8B, and 5.1A). Interestingly, PATZ1 regulated genes were 
significantly enriched in biological process GO terms, such as cell adhesion, neuron 
differentiation and cell morphogenesis (Table 4.1). These processes are known to be 
regulated by the basal level transcription activities of p53 and/or p53 familiy members 
120,129,130. This shows that PATZ1 interferes not only with DNA damage induced p53, 
but also with the basal level transcriptional activity of p53. Indeed, Nazli Keskin 
demonstrated that PATZ1 physically interacts with p53 even in the absence of any DNA 
damage induction. The defined biological processes, in which PATZ1 plays roles, also 
offer an explanation to the outcomes of PATZ1 deficiency. Consistent with our GO 
term analysis, PATZ1-null mice are born smaller in size and at a non-Mendelian 
frequency, suggesting a role for PATZ1 in development 101. Moreover these mice are 
born with defects in their central nervous systems, suggesting PATZ1 may play a role in 
neuron maintenance 98 and furthermore mESC with impaired expression of PATZ1 lose 
their pluripotency and start to differentiate, which are processes related to differentiation 
and morphogenesis 100. We found that PATZ1 modulates the DNA damage response 
and that PATZ1 deficiency results in an alteration of the expression of p53 target genes. 
We listed the biological process GO terms that are uniquely affected in PATZ1 
deficiency upon DNA damage induction and found that PATZ1 acts as a chromatin 
remodeling factor and during the DNA damage response PATZ1 functions more as 
transcription activator (Table 4.3 and 4.4 and Figure 5.1B and 5.1C). Many BTB-ZF 
family members interact with chromatin remodeling factors in order to induce changes 
in gene expression 131–133. However, whether PATZ1 recruited other chromatin 
remodeling factors to the DNA in our experiments remains to be elucidated. By 
combining the data we obtained in this study and the fact that PATZ1 physically 
interacts with the C-terminal regulatory region of p53 (shown by Nazli Keskin), it is 
possible that PATZ1 affects the DNA target specificity of p53 through altering the C-
terminal structure of p53. Although the C-terminal regulatory domain of p53 interacts 
with DNA in an unspecific manner and it assists the core DNA binding domain of p53 
on the genome, directing  it to the specific REs 34,134. Also, the extensive post-
translational modifications on the C-terminal regulatory domain of p53 define the 
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interaction partners of p53 and its overall stability 33,135. PATZ1 might be a regulator in 
these processes; however, this needs to be further studied.  
 
In order to create PATZ1 null human cell lines, we wanted to utilize a novel genome 
editing tool, TALENs (Transcription Activator-Like Effector Nucleases). In TALENs 
technology, a genomic locus of interest can be specifically and efficiently targeted to be 
modified using custom designed proteins 122. We created TALENs specifically against 
the human PATZ1 gene locus to knock out the gene expression (Figure 4.31 and 4.32). 
We delivered these proteins in to the HCT116 cell line and generated single cell derived 
colonies. We are in the process of screening these colonies for the mutations at the 
PATZ1 gene locus. As many other BTB-ZF family transcription factors, translocation or 
misexpression of the PATZ1 gene also favors tumorigenesis 136,137. These indications led 
us to investigate the direct role of PATZ1 in tumorigenesis. For this, we wanted to 
utilize murine xenograph models. We created PATZ1 overexpression or knocked down 
conditions in a mouse T cell lymphoma cell line, which is known to develop solid 
tumors once delivered in mice subcutaneously (Figure 4.34A and 4.34B). We will 
assess the progression of the tumor development and define the effects of PATZ1 in this 
process.  
 
In conclusion, our current study definitely identifies that the BTB-ZF family 
member transcription factor PATZ1 modulates the basal activity of p53 and in response 
to DNA damage. We clearly showed that the PATZ1 protein is lost upon DNA damage 
induction. We observed that it acts as a transcriptional repressor of the Thpok gene and 
it represses the transcriptional activity of p53 and that this inhibitory role of PATZ1 on 
the p53 protein is through the C-terminal domains of both proteins. These results 
demonstrate that PATZ1 modulates p53-dependent cellular stress and DNA damage 
pathways. 
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APPENDIX 
 
 
 
 
APPENDIX A: Chemicals Used in the Study 
 
 
 
Chemicals and Media Components Supplier Company 
2-Mercaptoethanol Sigma, Germany 
Acetic Acid Merck, Germany 
Acid Washed Glass Beads Sigma, Germany 
Acrylamide/Bis-acrylamide Sigma, Germany 
Agarose peQLab, Germany 
Ammonium Persulfate Sigma, Germany 
Ammonium Sulfate Sigma, Germany 
Ampicillin Sodium Salt CellGro, USA 
Bacto Agar BD, USA 
Bacto Tryptone BD, USA 
Boric Acid Molekula, UK 
Bradford Reagent Sigma, Germany 
Bromophenol Blue Sigma, Germany 
Chloramphenicol Gibco, USA 
D-Glucose Sigma, Germany 
Distilled water Milipore, France 
DMEM PAN, Germany 
DMSO Sigma, Germany 
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DNA Gel Loading Solution, 5X Quality Biological, Inc, USA 
DPBS CellGro, USA 
EDTA Applichem, Germany 
Ethanol Riedel-de Haen, Germany 
Ethidium Bromide Sigma, Germany 
Fetal Bovine Serum (FBS) Biological Industries, Israel 
Glycerol Anhydrous Applichem, Germany 
Glycine Applichem, Germany 
HBSS CellGro, USA 
HEPES Applichem, Germany 
Hydrochloric Acid Merck, Germany 
Isopropanol Riedel-de Haén, Germany 
Kanamycin Sulfate Gibco, USA 
LB Agar BD, USA 
LB Broth BD, USA 
L-Glutamine Hyclone, USA 
Liquid nitrogen Karbogaz, Turkey 
Magnesium Chloride Promega, USA 
Methanol Riedel-de Haen, Germany 
Monoclonal Anti-HA Antibody Sigma, Germany 
p53 Mouse Antibody Cell Signalling Technology, USA 
p53 Polyclonal Antibody Cell Signalling Technology, USA 
PATZ1 (H-300) Antibody Santa Cruz, USA 
Penicillin-Streptomycin Sigma, Germany 
Phenol-Chloroform-Isoamylalcohol Amersco, USA 
PIPES Sigma, Germany 
Potassium Acetate Merck, Germany 
Potassium Chloride Fluka, Germany 
Potassium Hydroxide Merck, Germany 
Protease Tablets (EDTA-free) Roche, Germany 
ProtG Sepharose Amersco, USA 
RNase A Roche, Germany 
RPMI 1640 PAN, Germany 
SDS Protein Gel Loading Pack Fermentas, Germany 
SDS Pure Applichem, Germany 
Skim Milk Powder Fluka, Germany 
Sodium Azide Amresco, USA 
Sodium Chloride Applichem, Germany 
SuperSignal Chemiluminescent Substrate Thermo Scientific, USA 
TEMED Applichem, Germany 
Tris Buffer Grade Amresco, USA 
Tris Hydrochloride Amresco, USA 
Triton X100 Promega, USA 
Tween20 Sigma, Germany 
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APPENDIX B: Equipment Used in the Study 
 
 
 
Equipment Company 
Autoclave Hirayama,Hiclave HV-110,Japan 
Balance Sartorius, BP221S, Germany 
Schimadzu, Libror EB-3200 HU, Japan 
Biomolecular Imager ImageQuant LAS 4000 mini - GE Healthcare, USA 
Cell Counter Cole Parmer, USA 
Centrifuge Eppendorf, 5415D, Germany 
Hitachi, Sorvall RC5C Plus, USA 
CO2 Incubator Binder,Germany 
Deepfreeze -80oC, Forma,Thermo ElectronCorp.,USA 
-20oC,Bosch,Turkey 
Distilled Water Millipore, Elix-S, France 
Electrophoresis Apparatus Biogen Inc., USA 
Biorad Inc., USA 
Electroporator Neon Transfection System - Life Technologies, USA 
Filter Membranes Millipore,USA 
Flow Cytometer BDFACSCanto,USA 
Gel Documentation Biorad, UV-Transilluminator 2000, USA 
Heater ThermomixerComfort,Eppendorf,Germany 
Hematocytometer Hausser Scientific,Blue Bell Pa.,USA 
Ice Machine Scotsman Inc., AF20, USA 
Incubator Memmert, Modell 300, Germany 
Memmert, Modell 600, Germany 
Laminar Flow Kendro Lab. Prod., Heraeus, HeraSafe HS12, Germany 
Liquid Nitrogen Tank Taylor-Wharton,3000RS,USA 
Magnetic Stirrer VELP Scientifica, ARE Heating Magnetic Stirrer, Italy 
Microliter Pipettes Gilson, Pipetman, France 
Eppendorf, Germany 
Microscope Olympus CK40,Japan 
Olympus CH20,Japan 
Olympus IX70,Japan 
 Zeiss Confocal LSM710, German 
Microwave Oven Bosch,Turkey 
pH meter WTW, pH540 GLP MultiCal, Germany 
Power Supply Biorad, PowerPac 300, USA 
Refrigerator Bosch,Turkey 
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Shaker Incubator New Brunswick Sci., Innova 4330, USA 
Spectrophotometer Schimadzu, UV-1208, Japan 
Schimadzu, UV-3150, Japan 
Thermocycler Eppendorf, Mastercycler Gradient, Germany 
Vortex Velp Scientifica,Italy 
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APPENDIX C: DNA and Protein Molecular Weight Markers 
 
 
 
 
Figure C.1: DNA and Protein Molecular Weight Markers 
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APPENDIX D: Cloning of PATZ1 cDNAs into pmigII-ires-mcherry Plasmid  
 
 
 
 
Figure D.1: Cloning of PATZ1 cDNAs into pmigII-ires-mcherry Plasmid. Patz1 cDNA 
was obtained from pCMV-HA-PATZ1 plasmid after digesting it with EcoRI restriction 
enzyme as shown on Figure E.1A. pMIGII_ires_cherry plasmid was digested with 
EcoRI. The EcoRI-digested-Patz1 cDNA was ligated into EcoRI-digested- 
pMIGII_ires_cherry plasmid. The new plasmid construct was digested with EcoRV and 
SmaI restriction enzymes, separately. EcoRV digestion gives a unique band at 1820bp 
and SmaI digestion gives a unique band at 1557bp. PATZ1-SDM constructs were also 
cloned into pMIGII_ires_cherry with this way.  
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APPENDIX E: Cloning of PATZ1 cDNA into pBABE-ires-Puro Plasmid  
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Figure E.1: Cloning of PATZ1 cDNA into pBABE-ires-Puro Plasmid. A. Patz1 cDNA 
was obtained from pCMV-HA-PATZ1 plasmid after digesting it with EcoRI restriction 
enzyme. The band of Patz1 cDNA (1989bp) is seen around 2000bp size on agarose gel. 
This band was extracted from the gel. B. pBABE-puro plasmid was digested with 
EcoRI. The linearized plasmid (5169bp), which is seen on agarose gel, was extracted 
from the gel. C. The EcoRI-digested-Patz1 cDNA was ligated into EcoRI-digested-
pBABE-puro plasmid. Ligation colonies were screened by EcoRV digestion. Correct 
bands should be 1810bp, 2650bp, and 2490bp. The colony, which is indicated with a 
red dot on top, was selected for further confirmation. It is digested with EcoRI and 
BamHI and the correct bands should be 1987bp for EcoRI digest and 1945bp for 
BamHI digest. 
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APPENDIX F: Cloning of PATZ1 shRNA into LMP Plasmid  
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Figure F.1: Cloning of PATZ1 shRNA into LMP Plasmid. We obtained Patz1 shRNA 
from OpenBiosystems Company, in pSM2 plasmid. A. EcoRI/XhoI double digest 
revealed the 110bp long shRNA. This band was extracted from the agarose gel. B. LMP 
plasmid was digested with EcoRI/XhoI. The linearized plasmid (7866bp), which is seen 
on agarose gel, was extracted from the gel. C. The EcoRI/XhoI-digested-Patz1 shRNA 
was ligated into EcoRI/XhoI-digested-LMP  plasmid. Ligation colonies were screened 
by SacII/XhoI double digestion. Correct bands should be 900 bp long (empty LMP 
plasmid gives a band at 800bp). 3rd and 4th colonies were selected for further 
confirmation. They were digested with EcoRI/XhoI, which shows the presence of the 
shRNA at 110bp. 
